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Abstract 
 
Epigenetic modifiers to augment the immunogenicity of chronic lymphocytic 
leukemia 
Cancer cells employ a litany of immunosuppressive and immunevasive strategies 
to avoid detection and elimination by the various arms of the innate and adaptive immune 
system.  Many hematologic and solid tumors progressively develop a specialized 
microenvironment which promotes tissue restructuring inflammation while masking the 
immune signature of the tumor cells themselves.  Chronic lymphocytic leukemia, a 
malignancy of mature B lymphocytes must constantly balance on the precipice of 
immune recognition.  A mature antigen presenting cell themselves, CLL clonal growth is 
dependent on the very interactions which, if effective, could potentially lead to their 
demise.  To circumvent this, CLL clones set up unique signatures which promote 
immune recognition yet provide diversionary signals to the remaining immune armament 
resulting in profound immune dysfunction. 
While the aforementioned immune dysfunction is widespread, the B cell and T 
cell repertoire are severely impaired during leukemic progression.  The lack of healthy B 
cells due to displacement by malignant B cells results in the obvious loss of an important 
antigen presenting cell as well as antibody-based immunity.  Additionally, deficient 
interactions with T cells result in anergy and the preponderance of improperly polarized 
T lymphocytes which are impotent to eliminate both pathogens and leukemic cells.  The 
viii 
result of such severe immune dysfunction is chronic infection and progressive disease 
which is the primary cause of death in CLL patients. 
Our research was focused on the premise that alleviating immune dysfunction and 
providing immunotherapeutic tools will significantly benefit CLL therapy.  To this end 
we developed methods to improve the cellular interaction between CLL cells and T cells 
a critical step towards improving the antigen presentation capacity of the diseased B cell 
repertoire.  We also identified a therapeutic strategy which can revert the anergic or 
improperly polarized state of T cells already in circulation allowing those cells to more 
effectively perform the effector functions necessary to fight pathogenic attack and 
malignant transformation.  Finally, we identified a number of novel targets in CLL which 
could be used in a vaccinate-induce method to license the elimination of CLL cells by the 
patient’s adaptive immune system.  To achieve our goals we utilized a relatively new 
class of drugs called epigenetic modifiers which specifically alter the chromatin structure 
resulting in novel genetic signatures which are heritable over cellular generations.  The 
unique properties of these drugs allow for the elicitation of suppressed genetic programs 
which, when properly controlled, have the potential to reassert healthy lymphocyte 
functions. 
Our studies provide a comprehensive therapeutic initiative which, by 
simultaneously alleviating the major causes of immune dysfunction in addition to 
facilitating the use of novel active immunotherapeutic strategies could potentially impact 
clinical therapy for CLL. 
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Chapter One: 
 
Introduction 
Tumor Immunology Overview 
Our view of tumor immunology underwent a dramatic change in the early 90’s 
given the surprising observations that most of the antigens expressed by tumor cells were 
not necessarily neo-antigens uniquely present in cancer cells, but rather tissue-
differentiation antigens also expressed in normal cells (Rosenberg 1995; Boon and van 
der Bruggen 1996). These unexpected findings led to the hypothesis that perhaps the 
greatest obstacles for harnessing the immune system against tumors were the complex 
mechanisms that establish T-cell tolerance against “self” tumor antigens. Experimental 
evidence supporting the above hypothesis was indeed provided by the Bogen’s and 
Levitsky’s groups who independently demonstrated that antigen-specific CD4+ T-cells 
were rendered unresponsive during tumor growth in vivo (Bogen 1996; Staveley-O' 
Carroll, Sotomayor et al. 1998). Following the initial report of this phenomenon termed 
“tumor-induced anergy”, several studies showed that this state of T-cell unresponsiveness 
also occurs during the growth of hematologic or solid tumors expressing model or true 
tumor antigens (Morgan, Kreuwel et al. 1998; Cuenca, Cheng et al. 2003; Overwijk, 
Theoret et al. 2003), during the progression of spontaneously arising tumors (Willimsky 
and Blankenstein 2005), and more importantly during the progression of human cancers 
(Lee, Yee et al. 1999; Noonan, Matsui et al. 2005).  This different view of tumor 
immunity also raised the bar for cancer immunotherapy, since the barrier imposed by 
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immune tolerance must be broken in order for the immune system to effectively 
recognize and eliminate tumors expressing mainly “self” antigens.  
More recently, several studies have provided important insights into the cellular 
and molecular mechanisms of tolerance induction and the composition and in vivo fate of 
the tolerized population(Rabinovich, Gabrilovich et al. 2007). For instance, at the cellular 
level, bone-marrow (BM) derived antigen-presenting cells (APCs) and regulatory T-cells 
(Tregs) have been implicated as playing a central role in tolerance induction. At the 
molecular level, signaling pathways involved in the regulation of pro- or anti-
inflammatory pathways in the APC have been shown to influence the ability of these 
cells to determine T-cell priming versus T-cell tolerance. Among those pathways, Stat3, 
c-kit, SOCS-1 and the zinc-finger A20 molecule have emerged as enticing molecular 
targets in APCs to overcome the remarkable barrier that tolerance to tumor antigens has 
imposed to cancer immunotherapy(Cheng, Wang et al. 2003; Wang, Cheng et al. 2005; 
Evel-Kabler, Song et al. 2006; Song, Evel-Kabler et al. 2008). 
A continued effort to identify molecular mechanism(s) regulating pro and/or anti-
inflammatory pathways in the APC would likely unveil additional targets to circumvent 
tumor-induced tolerance. Indeed, in recent years significant emphasis has been devoted to 
mechanistically understand regulation of pro-inflammatory/anti-inflammatory genes in its 
natural setting, the chromatin substrate. Although several mechanisms influence 
chromatin flexibility to allow dynamic changes in gene expression, chromatin 
modifications by acetylation/deacetylation of histone tails resulting in transcriptionally 
active or inactive chromatin play an important role in regulation of gene transcription, 
including genes involved in the inflammatory response(Foster, Hargreaves et al. 2007). 
3 
Similarly, DNA methylation status at the level of gene promoters also influences the 
transcriptional activity of inflammatory genes(Bruniquel and Schwartz 2003; Baguet and 
Bix 2004; Foster, Hargreaves et al. 2007).  Of note, inhibition of DNA methyltransferase 
1 (DNMT1) leading to hypomethylation of previously silenced chromatin has been 
associated not only with enhanced gene transcription but also with de-repression of 
antigens that could potentially serve as targets for cancer immunotherapy(Sigalotti, Fratta 
et al. 2004; Roman-Gomez, Jimenez-Velasco et al. 2007; Natsume, Wakabayashi et al. 
2008). The latter observations are particularly relevant for tumors arising from antigen-
presenting cells such as B-cell lymphomas and myeloid malignancies. In these cells, their 
antigen presenting capabilities could be enhanced via epigenetic manipulation with 
histone deacetylase inhibitors and/or hypomethylating agents that provide the double 
advantage of inducing de novo expression of tumor antigens such as cancer testis 
antigens (CTA), and enhance the expression of pro-inflammatory mediators resulting in 
an environment conducive to T-cell activation rather than T-cell tolerance. Importantly, 
re-activation of tumor antigens not previously seen by the immune system confers the 
additional opportunity to therapeutically target antigens that are less likely to induce T-
cell tolerance. Alternatively, the de novo expression of these tumor antigens in response 
to epigenetic modifiers might provide a temporal window to effectively harness T-cell 
immune responses with vaccination strategies before T-cell tolerance towards these 
antigens is ultimately established.  
Tumor Antigens 
Three tenants of a good antigen   
4 
When identifying the classical tumor vaccine antigen there are three critical 
characteristics that have the potential to dictate overall vaccine efficacy.   
I. The antigen must be of high antigenicity (Selvaraj, Yerra et al. 
2008).   
II. The antigen should be expressed in a significant percentage of the 
patient population, and  
III. The antigen must be expressed in tumor cells and required for tumor 
survival.   
Despite the seemingly obvious nature of these criterion, to date there have been 
few cancer vaccines that have satisfied all three.  Indeed, most of the targeted tumor 
antigens, including cancer-testis antigens, fail to satisfy one or more of these criteria.  
One of the primary reasons that these three factors are so difficult to fulfill is because 
they might be working against each other.  Take for instance, an antigen that is highly 
antigenic and is expressed on premalignant cancer cells.  In this scenario there are two 
possible outcomes for the developing tumor clone: it could either succumb to immune 
cell recognition and be eliminated, or it could actively suppress antigenicity utilizing a 
variety of escape mechanisms. Take again, the case where a particular tumor associated 
antigen (TAA) is expressed in a large percentage of tumors.  Given the vast heterogeneity 
inherent in the mammalian immune repertoire it is likely that such an antigen would 
maintain adequate central tolerance (and thus low antigenicity), otherwise the immune 
system would have already detected and eliminated cells expressing that particular 
antigen. Nevertheless, the fact that the tumor has progressed to a detectable level 
indicates the generation of significant peripheral tolerance. Finally, lets examine NY-
5 
ESO-1, perhaps the most clinically studied member of the CTA family (Gnjatic, 
Nishikawa et al. 2006) with more than 30 clinical trials performed in cancer patients. 
Vaccines and immunotherapies targeting NY-ESO-1 assume that the antigen might be 
expressed within 100% of the tumor cells, a lofty goal given that NY-ESO-1 is not 
considered necessary for the survival of the malignant clone(Nicholaou, Ebert et al. 
2006).  In addition, the silencing mechanism for NY-ESO-1 is known to be promoter 
hypermethylation, providing a relatively simple immune escape mechanism(Hong, Kang 
et al. 2005; Sigalotti, Coral et al. 2005). Finally, in light of recent reports of T-regulatory 
cell generation and the emergence of tolerogenic APCs, it is clear that peripheral T-cell 
tolerance generated by the tumor may be insurmountable using current modalities 
targeting NY-ESO-1(Gnjatic, Altorki et al. 2009).  Taken together, while our 
fundamental knowledge of tumor antigen expression and regulation has progressed 
significantly, our antigen choices and therapeutic modalities are moving to a much slower 
pace.  
Cancer Testis Antigens 
Cancer-testis antigens represent a large family of proteins with restricted 
expression to the germ-line and trophoblast. These antigens have been also found to be 
aberrantly expressed in certain solid and hematologic malignancies(Scanlan, Simpson et 
al. 2004).  This abnormal expression, it has been postulated, may confer the special 
function of “gametogenesis” to the developing malignancy, a theory reminiscent of the 
“trophoblastic theory of cancer” proposed by John Beard over a century ago(Gurchot 
1975).  According to this theory, CTA expression may provide a fitness advantage to 
cancer cells like independent assortment of chromosomes, limitless replicative capacity, 
6 
Figure 1: Shared characteristics of germ cells and cancer cells. Activation of the 
gametogenic programme (shown by brown cells) might contribute to properties of 
tumour formation and progression (shown by blue cells). Corresponding features 
between cancer cells and those in the germ cell/gamete/trophoblast differentiation 
pathways include: immortalization (involved in transformation), invasion, induction 
of meiosis (can lead to aneuploidy) and migration (contributes to metastasis). Shared 
phenotypes between germ cells and cancer cells include demethylation, angiogenesis 
induction, downregulation of the major histocompatibility complex (immune 
evasion), and expression of chorionic gonadotropin. The numbers (1–9) indicate 
gametogenesis- and tumorigenesis-related phenotypic traits and the stages at which 
these events occur. Figure and legend copied from (Simpson, Caballero et al. 2005). 
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tissue invasiveness, and increased motility (Figure 1) (Simpson, Caballero et al. 2005).  
MAGE-A1 is the founding CTA member discovered almost two decades by T. 
Boon and coworkers using a very laborious process that characterize the antigen 
specificity of tumor-infiltrating cytotoxic T-lymphocytes (TILs)(van der Bruggen, 
Traversari et al. 1991). Since then, more streamlined approaches for antigen discovery 
have been developed including the serological identification of antigens by recombinant 
expression cloning method (SEREX), differential gene expression analysis, high 
throughput immunoblot, and bioinformatics methods (Hubank and Schatz 1994; Sahin, 
Tureci et al. 1995; Scanlan, Gordon et al. 2002; Hoeppner, Dubovsky et al. 2006; 
Dubovsky, Albertini et al. 2007).  As a result of this concerted effort to identify, 
characterize, and classify CTAs, we now recognize 44 CTA families comprising over 89 
potential tumor antigens. 
Epigenetic regulation of CTAs 
CTA mRNA expression has been centrally linked to DNA methylation patterns 
within both the germ lineage and the cancer cell(Karpf and Jones 2002; Simpson, 
Caballero et al. 2005; Wischnewski, Pantel et al. 2006).  Two specific cytosine 
methylation changes occur in human malignancy, genome-wide hypomethylation and the 
eventual hypermethylation of specific promoter regions generally associated with tumor 
suppressor genes(Feinberg 1988; Feinberg, Gehrke et al. 1988; De Smet, De Backer et al. 
1996).  The former is of greater relevance to the expression of CTAs since it is believed 
that genome-wide hypomethylation is an early step in carcinogenesis and has the capacity 
to release chromatin constriction on a multitude of genetic elements(Woloszynska-Read, 
James et al. 2007).  CTAs which reside on the X chromosome (CT-X antigens) are 
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considered especially susceptible to epigenetic control in this manner, given the well 
understood processes of meiotic sex chromosome inactivation (MSCI) and meiotic 
silencing of unsynapsed chromatin (MSUC)(Scanlan, Gure et al. 2002; Turner 2007).  An 
additional class of autosomal CTAs has been linked to the expression of Brother of the 
Regulator of Imprinted Sites (BORIS).  Located on chromosome 20q13.2, a locus 
frequently amplified in cancer, and expressed predominantly in the testis, BORIS, is both 
a CTA and a possible oncogene(Klenova, Morse et al. 2002; Loukinov, Pugacheva et al. 
2002).  BORIS is considered a paralog of, and antithesis to, the CCCTC-binding factor 
(CTCF) which is primarily responsible for maintaining methylation insulator 
boundaries(Loukinov, Pugacheva et al. 2002; Woloszynska-Read, James et al. 2007).   
Immunotherapeutic interest in CTAs 
Since their discovery, the CTA genes have been primarily investigated for their 
ability to elicit anti-tumor immune responses.  The high antigenicity of CTAs is due to 
their restricted expression pattern.  The testis and trophoblast are considered 
immunologically privileged tissues.  In the case of germ cells, the lack of major 
histocompatibility complex (MHC) class I molecules effectively blinds peripheral 
tolerogenic mechanisms(Kowalik, Kurpisz et al. 1989).  In addition, the presence of the 
blood-testis barrier and the complete absence of CTA expression within the thymus serve 
to prevent CTA-specific tolerance at both the central and peripheral levels(Scanlan, 
Simpson et al. 2004).  This low basal tolerance and frequent overexpression in tumors 
makes CTA ideal candidates for anti-tumor vaccines or active immunotherapies. 
Much of the fervor surrounding CTAs comes as a result of the encouraging 
clinical trial obtained with vaccines targeting these antigens. NY-ESO-1 and the MAGE 
9 
family of antigens have been indeed evaluated in phase I and II clinical trials as anti-
tumor vaccines(Marchand, Weynants et al. 1995; Marchand, van Baren et al. 1999; Jager, 
Gnjatic et al. 2000; Coulie, Karanikas et al. 2002; Jager, Karbach et al. 2006).  Although 
tumor regressions have been observed in patients with metastatic melanoma, the most 
frequent result was generation of robust anti-CTA CD4 and CD8 T-cell responses 
(Marchand, Weynants et al. 1995; Marchand, van Baren et al. 1999; Jager, Gnjatic et al. 
2000; Jager, Nagata et al. 2000; Coulie, Karanikas et al. 2002; Chen, Jackson et al. 2004; 
Davis, Chen et al. 2004; Huarte, Karbach et al. 2004; Kruit, van Ojik et al. 2005; van 
Baren, Bonnet et al. 2005; Jager, Karbach et al. 2006).  A recent study conducted by 
Gnjatic et. al. brought to light the fact that, in addition to robust cytolytic T-lymphocytes, 
CTA based vaccination also induces CD4+CD25hi T-regulatory cells that potentially 
blunt clinical responses(Gnjatic, Altorki et al. 2009).  One possible workaround could be 
the use of humanized monoclonal antibody anti-CTLA4 therapy, which in clinical trials 
has been found to elicit robust NY-ESO-1 reactivity and improve the balance of 
regulatory (Treg) to activated CD4 T-cells(Liakou, Kamat et al. 2008; Fong, Kwek et al. 
2009).  Notably, recent evidence supports the spontaneous generation of CTA-specific 
CD4 T-cells with cytotoxic capabilities in patients treated with anti-CTLA4 (Huarte, 
Karbach et al. 2004).  This finding is specially promising given that a number of the 
CTAs were discovered using SEREX which provides indirect evidence of CD4 T-cell 
recognition. It is plausible therefore that an intact and functional repertoire of CD4 T-
cells specific to CTAs might exist in many cancer patients(Dubovsky, McNeel et al. 
2009). 
Immunological Effects of Epigenetic Modifiers  
10 
Demethylating Agents  
Demethylating agents, or DNA methyltransferase inhibitors (DNMTi), were 
initially investigated in the late 60’s and early 70’s as purine analogs with the potential to 
block DNA and/or RNA synthesis(Sorm and Vesely 1968; Vesely, Cihak et al. 1968; 
Vesely, Cihak et al. 1970).  It was not until the 1980’s that the differentiating capacity of 
these drugs was truly appreciated(Jones and Taylor 1980).  It was later found that 5-aza-
2’-deoxycytidine (5A2) and 5-aza-2’-cytidine (5AC) were non-competitive inhibitors of 
DNMT1, eliciting the development of a thioether bond at C-6 covalently linking the 
enzyme to the DNA strand and functionally inactivating it(Ferguson, Vertino et al. 1997).  
DNMT1 is considered the primary methyltransferase enzyme responsible for propagating 
the methylome to daughter cells after mitotic division(Luczak and Jagodzinski 2006). 
Thus, inhibition of DNMT1 results in the hypomethylation of previously silenced 
chromatin which is believed to directly facilitate cytotoxicity in cancer cells.  More 
specifically, critical tumor suppressor proteins such as p16 and p15INK4B are postulated 
to induce abrupt cell cycle arrest after treatment with DNMTi(Claus, Almstedt et al. 
2005).  Moreover, the ability of specific inhibitors, namely 5-azacytidine (5AZA) to 
interrupt RNA synthesis gives them anti-metabolite characteristics as well. 
While demethylation of the promoter region is the most studied phenomenon 
associated with DNMTi there are numerous proposed mechanisms by which they may 
enable the reactivation of genes.  DNMTi also effectively inhibit Methyl-CpG binding 
domain (MBD) proteins which serve as mediators of transcriptional repression(Hendrich 
and Bird 1998).  MBDs recruit transcriptional co-repressors such as histone deacetylases 
and Sin3a to the chromatin facilitating the assembly of repressive chromatin structures 
11 
onto the DNA(Jones, Veenstra et al. 1998; Ng, Zhang et al. 1999).  An additional 
mechanism results due to the allosteric inhibition of transcriptional repressor domains 
located within DNMT1, 3a, and 3b which normally facilitate chromatin constriction 
similar to MBDs(Fuks, Burgers et al. 2000; Robertson, Ait-Si-Ali et al. 2000; Rountree, 
Bachman et al. 2000; Bachman, Rountree et al. 2001).  More notably, the mechanisms 
attributed to DNMTi have unveiled previously unknown links between DNA 
methylation, histone acetylation, and chromatin constriction. 
Demethylating Agents and CTA Expression 
From an immunotherapeutic perspective DNMTi have received attention due to 
their ability to enhance or induce CTA expression in cancer(Weber, Salgaller et al. 1994).  
Evidence generated in multiple laboratories indicates that DNMTi-induced CTA 
expression may be cancer specific in nature(Vatolin, Abdullaev et al. 2005; Dubovsky 
and McNeel 2007).  These data has been confirmed in studies conducted by Karpf and 
collaborators using microarray analysis of normal epithelial cells and cancer cells 
exposed to 5A2(Karpf and Jones 2002; Karpf, Lasek et al. 2004).  In addition, studies 
conducted by our group indicate that, in human malignancy, expression of CTAs can 
persist for weeks to months after treatment with DNMTi(Dubovsky and McNeel 2007).  
The molecular mechanisms which underlie the cancer-specificity and longevity of CTA 
expression post treatment have yet to be fully elucidated; however the prevailing 
hypothesis involves cancer-specific induction of BORIS expression following DNMTi 
treatment.  It has been found that the BORIS promoter becomes increasingly 
hypomethylated as cancer progresses(Woloszynska-Read, James et al. 2007). A 
preexisting hypomethylated state could conceivably lead to BORIS expression in a 
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cancer-specific manner following limited treatment with DNMTi.  Since BORIS 
competes for the same 11ZF binding site as CTCF, once BORIS is expressed it may 
perpetuate the expression of CTAs post DNMTi treatment(Loukinov, Pugacheva et al. 
2002; Vatolin, Abdullaev et al. 2005).  Supporting this concept, tumor suppressor 
proteins unrelated to CTAs are re-silenced by promoter methylation following halt of 
DNMTi treatment. In contrast, CTAs themselves remain hypomethylated, implicating 
that a master regulator is induced which can specifically perpetuate CTA 
hypomethylation(Hong, Kang et al. 2005). 
Immunomodulatory activity of Demethylating Agents 
Equally valuable from an immunotherapeutic perspective is the recapitulation of 
the interferon (IFN) pathway in cancer cells treated with DNMTi.  Epigenetic 
suppression of the IFN response has been shown to be a frequent and deleterious result of 
malignancy (Lee and O'Neill 1987; Reid, Merigan et al. 1992; Karpf, Peterson et al. 
1999; Katzenellenbogen, Baylin et al. 1999; Lu, Au et al. 2000; Morris, Spangler et al. 
2000; Liang, Gonzales et al. 2002; Kulaeva, Draghici et al. 2003; Reu, Bae et al. 2006; 
Reu, Leaman et al. 2006).  In an attempt to identify expression signatures which represent 
signal transduction pathways it was discovered that the expression of IFN pathway genes 
is an indirect effect of 5A2 treatment(Karpf, Peterson et al. 1999).  Induction of the IFN 
pathway can increase tumor immunosurveillance and antigenic peptide presentation.  In 
addition, our group has shown that the costimulatory profile of certain hematologic 
malignancies can be rescued using DNMTi, corroborating data obtained by Coral et. al. 
in melanoma (Coral, Sigalotti et al. 1999; Dubovsky, McNeel et al. 2009).  Our results, 
albeit demonstrated in a B-cell malignancy, point to the possibility of induce and/or 
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augment the antigen-presenting capabilities of tumor cells leading to enhanced priming of 
antigen-specific immune responses(Dubovsky, Wang et al. 2009).  In addition, DNMTi-
induced IFN signaling and costimulatory expression may further increase the level of 
CTA peptide presentation amongst cancer cells aiding in the formation of a robust anti-
cancer immune response. 
Histone Deacetylase Inhibitors 
Histone Deacetylases (HDACs) 
Chromatin structure is determined by covalent and non-covalent modifications of 
the DNA itself (DNA methylation, destabilization of double-strand) or by changes in 
proteins associated to DNA (acetylation, methylation, and phosphorylation). One of these 
DNA-associated proteins is histones, who are targets for numerous covalent and non-
covalent modifications that ultimately affect the status of the chromatin structure. 
Acetylation of positive amino acids is one of the covalent modifications on histones. This 
enzymatic reaction mediated by histone acetyltransferases (HATs) results in 
transcriptionally active chromatin. Conversely, removal of the acetyl group mediated by 
histone deacetylases leads to histone hypoacetylation and transcriptionally inactive 
chromatin. Thus, histone acetylation patterns have a central role in modulating chromatin 
accessibility, gene expression and, as a result, cellular phenotype.   
In the progression of cancer, hypoacetylation results in the silencing of selected 
genes which would otherwise decrease the clonotypic survival advantage(Liu, Kuljaca et 
al. 2006).  HDACs comprise a family of enzymes recruited by co-repressors or by multi-
protein transcriptional complexes to gene promoters where they regulate transcription 
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Figure 2: Human histone deacetylases enzymes (HDACs).  the class I (HDAC1, 2, 
3 and 8), class IIa (HDAC4, 5, 7 and 9), class IIb (HDAC6 and 10) and class IV 
(HDAC11) HDACs with the various structural/functional domains listed. The capacity 
of structurally diverse HDACi to inhibit the activity of different HDAC classes or 
specific HDACs is also shown.  Figure and legend copied from (Bolden, Peart et al. 
2006). 
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through chromatin modification without directly binding DNA.  Approximately twenty 
HDACs have been identified, and they are divided into four principal classes (Figure 2) 
(Bolden, Peart et al. 2006).  Class I HDACs include HDAC1, 2, 3 and 8, class II HDACs 
include HDAC4, 5, 6, 7, 9 and 10, class III HDACs are members of the sirtuin family of 
HDACs, among which yeast Sir2 is the founding member, and Class IV, represented by 
HDAC11, the newest HDAC discovered (Bolden, Peart et al. 2006).   Histones are the 
main substrates for the enzymatic activity of HDACs. However, several studies have 
shown that HDACs also deacetylate non-histone proteins such as p53, E2F1, RelA, YY1, 
TFIIE, BCL6 and TFIIF. In addition each member is also capable of exerting a variety of 
other cellular functions related to their deacetylase activity, tissue expression profile, 
cellular compartment distribution, stage of cellular differentiation and/or 
pathophysiological conditions (Glozak, Sengupta et al. 2005; Minucci and Pelicci 2006). 
As an example, HDAC6 is mainly localized in the cell cytoplasm and it is uniquely 
endowed with tubulin deacetylase activity(Hubbert, Guardiola et al. 2002). This HDAC is 
a key regulator of cytoskeleton, cell migration and cell-cell interaction(Valenzuela-
Fernandez, Cabrero et al. 2008) and, in immune cells plays a role in the organization of 
the APC/T-cell immune synapse(Serrador, Cabrero et al. 2004). Similarly, HDAC11, the 
newest member of the HDAC family, is a transcriptional repressor of IL-10 gene 
expression in antigen-presenting cells(Villagra, Cheng et al. 2009) and, it has been found 
to be tissue-restricted and uniquely expressed in the brain, kidney, testis and abnormally 
over-expressed in certain types of leukemias and lymphomas(Gao, Cueto et al. 2002).    
HDAC inhibitors  
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HDACs are the target of several structurally diverse compounds known as HDAC 
inhibitors (HDACi)(Marks, Richon et al. 2000). Of note, these compounds were used as 
inhibitors long before a clear understanding of the role of specific HDACs in normal 
and/or transformed cells began to emerge. Existing HDACi can induce 
cytodifferentiation, cell cycle arrest and apoptosis of transformed cells (Marks, Richon et 
al. 2000; Bolden, Peart et al. 2006). Clinical use of HDACi have shown potent and 
specific anti-cancer activities partially due to the upregulation of cyclin-kinase inhibitor 
p21, induction of proaptotic BCL2 family proteins, repression of angiogenic factors such 
as vascular endothelial growth factor (VEGF), and inhibition of transcription factors such 
as nuclear factor kappa B (NF-κB) (Sambucetti, Fischer et al. 1999; Richon, Sandhoff et 
al. 2000; Chen, Fischle et al. 2001; Kim, Kwon et al. 2001; Ruefli, Ausserlechner et al. 
2001; Chen, Mu et al. 2002; Deroanne, Bonjean et al. 2002; Peart, Tainton et al. 2003; 
Yeung, Hoberg et al. 2004; Hoberg, Popko et al. 2006) Of note, one compound, SAHA, 
is the first HDAC inhibitor approved by the FDA for the treatment of patients with 
cutaneous T-cell lymphomas(Mann, Johnson et al. 2007; Marks and Breslow 2007). In 
spite of these important therapeutic advances, the underlying target(s) and/or 
mechanism(s) mediating the antitumor activity of HDACi in human malignancies remain 
to be fully elucidated.  
The regulatory role of particular HDACs and the therapeutic use of HDACi is not 
restricted to cancer since several studies have also shown that HDACs play a role in 
autoimmune diseases (Bhavsar, Ahmad et al. 2008), inflammatory regulation (Blanchard 
and Chipoy 2005), central nervous system disorders(Kazantsev and Thompson 2008), 
and during development (Haberland, Montgomery et al. 2009). Supporting this concept, 
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HDACi have emerged as a potential therapeutic tools for the treatment of autoimmune 
diseases (Bhavsar, Ahmad et al. 2008) (Mishra, Brown et al. 2001), cystic fibrosis 
(Rubenstein and Zeitlin 1998), muscular dystrophy (MDX) (Minetti, Colussi et al. 2006) 
and in regulation of immune tolerance (Tao and Hancock 2007).  In summary, the 
increasingly recognized participation of HDACs in regulation of several cellular 
functions, make the ever-expanding variety of HDACi amongst the most promising drugs 
currently under investigation (Glozak and Seto 2007).   
HDACi as immunomodulatory drugs 
In contrast to the rapidly increasing knowledge of the role of HDACs in cancer 
biology and the use of HDACi in cancer and other pathological conditions, little is still 
know about the role of specific HDACs in immune cells and the functional consequences 
of their inhibition by HDACi. Of note, while some studies have highlighted the ability of 
particular HDACi to augment inflammatory and antitumor responses, other studies have 
shown the opposite, ie., HDACi display anti-inflammatory properties and can ameliorate 
the severity of graft-versus-host disease (GVHD) and autoimmune disorders. Among the 
former studies, seminal work performed by T. Tomasi’s lab demonstrated that treatment 
of immune cells and some tumor cells with tricostatin A (TSA) induce the expression of 
MHC class I and II, the costimulatory molecules CD80, CD86, and CD40, the 
immunoproteosome subunits LMP2 and LMP7 and the peptide loading machinery TAP1 
and TAP2(Magner, Kazim et al. 2000; Magner and Tomasi 2000; Khan, Magner et al. 
2004; Tomasi, Magner et al. 2006; Khan, Magner et al. 2007; Khan, Gregorie et al. 2008; 
Khan and Tomasi 2008).  These results indicate that this particular HDACi can 
functionally replace the histone acetyltransferase activity of CIITA, CBP, p300, and 
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PCAF, thus allowing MHC class II activation.  In addition, our group recently 
investigated the antigen-presenting capabilities of malignant B-cells from patients with 
chronic lymphocytic leukemia (CLL) and found that LAQ824, a member of the 
hydroxamic acid analog family of HDACi,  was capable of significantly increase the 
APC function of malignant B-cells resulting in increased priming of T-cells (Dubovsky, 
Wang et al. 2009).  Furthermore, we have recently found that treatment of professional 
APCs with LBH589, SAHA, and LAQ824 (all belonging to the hydroxamic acid analog 
family) inhibit the secretion and transcription of immunosuppressive factors such as IL-
10 while simultaneously increasing the production of the pro-inflammatory cytokines IL-
12p70, IL-1α, IL-1β, IL-2, GM-CSF, TNFα, and RANTES in a dose dependent manner 
(Wang et al. Unpublished data).  Taking together, the positive immunological effect of 
these particular HDACi might play to the advantage of CTA-based immunotherapy and 
as such studies combining CTA based vaccine modalities with HDACi are currently 
ongoing in our lab.  
In contrast with the above results, evidence also exists linking some classically 
studied HDACi with immunosuppressive effects. For instance, HDACi can inhibit the 
production of inflammatory mediators such as tumor necrosis factor-α, interleukin-1, and 
interferon-γ in the setting of graft-versus host disease, an outcome with direct clinical 
benefit for the treatment of this complication in patients undergoing an allogenic bone 
marrow transplant (Reddy, Maeda et al. 2004; Li, Zhao et al. 2008).  Of note, the anti-
inflammatory properties of HDACi did not impacted upon graft-versus leukemia (GVL) 
effect, which was surprisingly found to be enhanced in these studies.  
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The seemingly contradictory effects of HDACi upon inflammatory responses 
could be a reflection of several factors, ie. the pan-HDAC inhibitory effect of the 
compounds currently in use, resulting in a myriad of cellular effects that likely would 
differ based on HDACs expression in particular immune cells, the stage of cellular 
differentiation and/or activation at the time of exposure to HDACi, and the dose and/or 
length of exposure to HDACi in vitro and or in vivo among others. Complicating this 
picture even further, there is now evidence that the role of specific HDACs in immune 
cells goes beyond their initially described effects on histones and now encompass more 
complex regulatory functions, like the propensity for certain HDACs to directly acetylate, 
and thereby regulate, key immunologically relevant transcription factors such as STAT1, 
STAT3, and NFκB (Chen, Fischle et al. 2001; Nusinzon and Horvath 2003; Yuan, Guan 
et al. 2005).  
Given the above scenario, dissection of the relevant mechanism(s)/target(s) 
involved in the divergent inflammatory effects of pan-HDACi would be challenging and 
difficult to achieve. To try to overcome this obstacle, we have recently pursued a 
different approach in which we have first identified the role of specific HDACs in the 
transcriptional regulation of a particular inflammatory/anti-inflammatory gene. Following 
this step, we have next pursued mechanistic studies leading to the evaluation of the 
immunological effects of more specific HDACi targeting particular HDACs. Under this 
approach, we recently over-expressed or knocked-down specific HDACs in antigen-
presenting cells and determined the expression of IL-10, cytokine that plays a central role 
in tolerance induction and regulation of inflammatory responses. We have found that 
among all the HDACs evaluated, HDAC11 by interacting at the chromatin level with the 
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distal region of the IL-10 promoter, down-regulates IL-10 transcription in murine and 
human APCs(Villagra, Cheng et al. 2009).  In addition, we found that over-expression of 
HDAC6 induce the opposite effect, i.e. transcriptional activation of IL-10 gene 
expression (Villagra et al. Manuscript in preparation). The significance of these findings 
lies at several levels: First, it has provided a physiological role for HDAC11, the newest 
member of the HDAC family, with previous unknown function. Secondly, HDAC11 and 
HDAC6 by inducing dynamic changes at the chromatin level regulate the expression of 
IL-10, (and perhaps other genes involved in the inflammatory response), effect that might 
explain -at least in part- the plasticity of the APC to determine T-cell activation versus T-
cell tolerance. Third, HDAC11 and HDAC6 represent novel molecular targets for more 
specific HDACi to potentially influence immune activation versus immune tolerance, a 
critical decision with significant implications not only for cancer immunotherapy but also 
for the transplantation and autoimmunity fields.  
Histone acetylation and T-lymphocyte polarization 
Of equal immunologic importance is the proper polarization of anti-cancer 
immune reactivity.  HDACi have shown divergent effects on this front as well. For 
instance, studies conducted by Edens et. al. suggest that TSA is particularly potent at 
inducing T-cell anergy (Edens, Dagtas et al. 2006).  A potential mechanism is that 
excessive expression of p21 inhibits the proliferation of responder lymphocytes (Jackson, 
DeLoose et al. 2001; Gilbert, Boger et al. 2005).  In contrast, we have recently found that 
the HDACi LAQ824 can reverse antigen-specific anergy, rendering previously tolerized 
T-cells functional (Wang et al. Manuscript in preparation). Furthermore, studies in 
malignant CLL cells have shown that disruption of histone deacetylase enzymes can shift 
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the polarization of anti-cancer CD4+ lymphocyte responses from Th2 to Th1(Dubovsky, 
Wang et al. 2009). These differential effects are likely related to differences in the 
inhibition profile of the HDACi used.   
Several groups have recently demonstrated an increased frequency and potency of 
CD4+CD25hi T-regulatory cells after treatment with HDACi(Tao and Hancock 2007; 
Reilly, Thomas et al. 2008; Samanta, Li et al. 2008; Wang, Lee et al. 2009).  Additional 
evidence suggests that HDACi can inhibit the autoimmune component of a variety of 
diseases including systemic lupus erythematosus, concanavalin A induced hepatitis, 
experimental autoimmune encephalomyelitis, rheumatoid arthritis, and colitis (Leoni, 
Zaliani et al. 2002; Chung, Lee et al. 2003; Reilly, Mishra et al. 2004; Camelo, Iglesias et 
al. 2005; Glauben, Batra et al. 2006; Leng, Gries et al. 2006).  These results are likely 
related to the inhibition of HDAC 9, which was recently shown to deacetylate key lysine 
amino acids in the forkhead domain of FOX-P3 reducing the functional capacity of T-
regulatory cells(Tao and Hancock 2007).  Reminiscent of our studies of the role of 
particular HDACs in APCs, these studies in T-cells shed light on the differential roles of 
specific HDACs and serve to direct future efforts at generating more specific HDACi 
which could directly benefit immunotherapy and minimize off-target immunosuppressive 
effects.  
Crosstalk between HDAC activity and DNA methylation 
Although the biochemical pathways which facilitate DNA acetylation are distinct 
from those which regulate DNA methylation, evidence supports a relationship between 
the two systems that plays a role in modulating gene repression programming(Cedar and 
Bergman 2009).  This recently unveiled link between DNA methylation and the histone 
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code led investigators to induce CTA expression in malignant cells using HDACi.  It has 
now been demonstrated in both solid and hematologic malignancies that CTA expression 
can be achieved using a variety of clinically relevant HDACi (Weiser, Ohnmacht et al. 
2001; Fradet, Picard et al. 2005; Wischnewski, Pantel et al. 2006; Dubovsky, Wang et al. 
2009; Oi, Natsume et al. 2009).  At the same time it became clear that combination of 
HDACi and DNMTi might served to synergistically activate CTA expression in 
cancer(Weiser, Guo et al. 2001; Dubovsky, Wang et al. 2009; Oi, Natsume et al. 2009).  
The mechanism(s) underlying this synergism was shown to be concordant DNA 
hypomethylation and histone acetylation of CTA promoter regions, namely those within 
the MAGE CTA family(Claus, Almstedt et al. 2005; Wischnewski, Pantel et al. 2006).  
Thus, the combination of HDACi and DNMTi is a promising venue for enhancing CTA-
based immunotherapeutic approaches. 
The “vaccinate-induce” model 
One critical lesson learned from vaccine against microorganisms is that successful 
vaccination requires delivery of the vaccine and the induction of long lasting 
immunological memory prior to pathogenic challenge (“preventive vaccination”) 
(O'Donnell and DeWolf 1995; Plotkin 1999).  Whereas this ideal scenario once seemed 
impossible in the setting of therapeutic cancer vaccines, the advent of epigenetic 
modifiers has brought to light a novel immunotherapeutic strategy.  A refreshed 
perspective on active immunotherapy incorporates the classical tenants of cancer-
specificity and high antigenicity with the novel concept of forced antigen expression by 
using epigenetic modifiers.  This particular immunotherapeutic modality that our group 
has termed “vaccinate-induce” is supported by recent studies by Guo et. al. who 
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demonstrated that de novo induction of the murine CTA, P1A, using the demethylating 
agent 5A2 can be combined with adoptive immunotherapy to achieve therapeutic benefit 
(Guo, Hong et al. 2006; Coral, Sigalotti et al. 2007).  This approach resulted not only in 
the expansion of P1A specific cytolytic T-cells but also in the reduction of metastatic 4T1 
mammary tumor nodules in tumor bearing mice. In parallel to the Guo’s report, a 
plethora of studies have recently identified CTAs which were inducible in particular 
malignancies, drastically expanding the list of potential vaccine antigen candidates 
(Wischnewski, Pantel et al. 2006; Dubovsky and McNeel 2007; Adair and Hogan 2009; 
Oi, Natsume et al. 2009).  Shortly thereafter, a group from Nagoya University in Japan 
published similar results in an orthotopic glioma model (Natsume, Wakabayashi et al. 
2008).  A key scientific feature of this study was the utilization of the human CTA, NY-
ESO-1, further demonstrating the relevance of such an approach to human malignancy.  
Most recently, Richard Morgan’s group, in collaboration with David Schrump and Steven 
Rosenberg demonstrated similar NY-ESO-1 based cytolytic ability in an in vitro system 
using a variety of epithelial malignancies; promising precursory evidence for future 
evaluation in the clinical setting (Wargo, Robbins et al. 2009).  The significant 
advancement of this study was the evaluation of a combination DNMTi/HDACi therapy, 
namely 5A2 and depsipeptide. The results indicated that there was a significant 
advantage, in terms of CTL IFNγ production, to 5A2/DP therapy in pancreatic, ovarian, 
and glioblastoma cancers.   
As it stands, there are no published reports supporting the hypothesis that 
vaccination, as apposed to adoptive transfer, will potentiate similar effects. However, in 
preliminary experiments we have found that the in vivo combination of HDACi with a 
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vaccination strategy resulted in tumor rejection, an effect that was not seen in animals 
treated with HDACi or vaccine alone. In addition, this approach was associated with very 
low toxicity to normal tissues reaffirming the safety of epigenetic therapy combined with 
active immunotherapy. Needless to say, studies which focus efforts on diversifying the 
immunotherapeutic approaches that can accompany epigenetic modifier treatment are 
currently underway.  On an additional note, the vast majority of studies thus far have 
focused on solid tumors, however our laboratory has recently generated data which 
supports the use of a vaccinate-induce therapy in the treatment of hematologic 
malignancies. 
The potential benefits of such vaccinate-induce therapeutic model combining 
vaccines with epigenetic modifiers are listed below: 
I. De novo induction of CTAs represents a means to avoid peripheral 
tolerogenic mechanisms induced by the tumor 
II. Use of CTAs avoids central tolerance  
III. Forced CTA expression inhibits the rapid generation of tumor escape 
variants 
IV. Induction of CTA expression expands the patient population for which a 
particular vaccine strategy might be effective 
V. Intratumoral heterogeneity can be overcome via tumor-wide epigenetic 
induction, and  
VI. Immunomodulatory effects of epigenetic modifiers (ie. increased signal one, 
increased signal 2 or co-stimulatory molecules and increased signal 3 or pro-
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inflammatory mediators) would likely enhance CTA presentation to the 
immune system. 
Chronic lymphocytic leukemia 
Chronic lymphocytic leukemia (CLL) is the most common B-cell malignancy in 
the Western world and is characterized by a progressive accretion of long-lived mature B 
lymphocytes with a low proliferation rate (Krackhardt, Witzens et al. 2002; Jemal, Siegel 
et al. 2008; Ouillette, Erba et al. 2008; Ramsay, Johnson et al. 2008).  Even with today’s 
therapies, CLL remains incurable, and patients almost invariably succumb to the disease 
(Cheson 1994; Rossmann, Lewin et al. 2002).  The classical clinical staging system 
developed by Rai and Binet has been able to predict the long-term survival of patients 
with CLL but has failed to predict the specific disease course in patients with early-stage 
CLL (Rai, Sawitsky et al. 1975; Binet, Auquier et al. 1981). Recent advances in 
cytogenetic and biomarker discovery are helping to better predict disease progression and 
survival in such heterogenic patient populations.  Cytogenetic analysis by fluorescence in 
situ hybridization (FISH) is widely used to identify the more common chromosomal 
aberrations, primarily deletions in 13q14, 11q23 (ATM), 17p13 (p53), 6q, and trisomy 
12.  Deletion of 17p13 is associated with chemotherapy resistance, rapid disease 
progression, and inferior survival (Dohner, Stilgenbauer et al. 2000).  In addition, the 
mutational statuses of the Ig heavy chain, ZAP70, and CD38 expression are important 
prognostic factors for CLL, which can be used to differentiate patients with poor 
prognosis (Dohner, Stilgenbauer et al. 2000; Zenz, Mertens et al. 2008).  First-line 
treatments with purine analogs such as fludarabine or pentostatin in combination with 
alkylating agents and or monoclonal antibodies against CD20 can result in high response 
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rates, but not a clear survival benefit (Kay, Rai et al. 2006).  Furthermore, this approach 
is not considered curative, and the inevitable relapse is typified by immune dysfunction, 
myelosupression, and outgrowth of chemotherapy-resistant CLL clones (Kater, van Oers 
et al. 2007).   
B-cell dysfunction 
In healthy individuals B-lymphocytes are proficient stimulators of antigen 
specific Th1 T-cell responses capable of eliminating virally infected or neoplastic cells 
via direct cellular cytotoxicity (Mosmann and Coffman 1989).  However, in CLL an 
increasingly immunosuppressive phenotype enables the malignant B-cell to evade 
immune detection(Krackhardt, Witzens et al. 2002; Scrivener, Goddard et al. 2003; 
Mellstedt and Choudhury 2006; Horna and Sotomayor 2007).  Mounting evidence points 
to specific defects in the antigen presenting cell (APC) functions including decreased 
self-peptide presentation, improper T-cell synapse formation, deficient costimulation, and 
diversionary cytokine signaling.   
Although the distinct molecular mechanisms which elicit CLL-induced 
immunosupression remain unclear, recent evidence supports the notion that chromatin 
constriction of critical immunostimulatory factors may be involved(Rush, Raval et al. 
2004; Chen, Raval et al. 2009).  Moreover, promoter hypermethylation and histone 
hypoacetylation are primary mechanisms for silencing highly antigenic protein products 
which promote the immune recognition of malignant cells.  Novel strategies have been 
suggested which may supplant immunosupression with effective cancer-antigen 
presentation leading to robust T-cell activation and prolonged killing(Khan, Magner et al. 
2004; Khan, Magner et al. 2007; Wierda and Kipps 2007).  The hallmarks of such 
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strategies hinge upon functionally increasing the APC capacity of CLL cells by reducing 
the levels of immunosuppressive factors, generating a robust response against a non-
tolerized cancer-specific antigen, and properly polarizing the resulting primed T-cells.  
Recent studies have demonstrated increased expression of MHC class I class II, 
immunoproteosome subunits, peptide processing machinery, pro-apoptotic molecules 
such as APO2L/TRAIL, and various costimulatory molecules after treatment with a 
histone deacetylase inhibitor (HDACi) leading to enhanced cancer-specific immune 
responses(Borden 2007; Khan, Gregorie et al. 2008; Khan and Tomasi 2008).  
Additionally, both HDACi and DNA methyltransferase inhibitors (DNMTi), such as 5-
aza-2’-deoxycytidine (5A2), have proven capable of inducing long lasting, cancer-
specific, expression of a highly antigenic class of proteins, termed cancer-testis antigens 
(CTAs)(Dubovsky, McNeel et al. 2009).  Published studies demonstrate that this effect 
alone may potentiate effective anti-cancer immune responses(Guo, Hong et al. 2006).  .  
Furthermore, a role for epigenetic modifiers in the regulation of pro-inflammatory 
cytokines has also been demonstrated(Sailhamer, Li et al. 2008; Villagra, Cheng et al. 
2009).  There currently exists a single clinical trial investigating the efficacy of 5-aza-2’-
deoxycytidine in combination with the HDACi valproic acid in previously treated CLL 
patients, the final results of this trial are still pending(Blum, Liu et al. 2010). 
T-cell dysfunction 
In healthy individuals B-lymphocytes are critically necessary for the polarization 
of effective T cell responses (Mosmann and Coffman 1989).  However, in CLL an 
increasingly defective immune synapse enables the malignant B-cell to evade immune 
detection by inducing T cell anergy as well as improper Th2 polarization (Krackhardt, 
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Witzens et al. 2002; Scrivener, Goddard et al. 2003; Mellstedt and Choudhury 2006; 
Horna and Sotomayor 2007).  The end result of this immunosupression is a high 
incidence of severe infections that in the setting of therapeutic interventions, often lead to 
patient morbidity. (Kay, Rai et al. 2006; Fulci, Chiaretti et al. 2007; Ouillette, Erba et al. 
2008; Rassenti, Jain et al. 2008). 
Original identification of the Th1 and Th2 T cell subsets established disparate 
patterns of stimulation underpinned by static and heritable epigenetic changes (Wilson, 
Rowell et al. 2009).  More recently, however, the widely observed plasticity in Th cell 
differentiation was nailed down to bivalent epigenetic marks that maintained heritability 
yet provided the flexibility to tailor activation status based upon changing external signals 
(Araki, Wang et al. 2009). Surprisingly, these bivalent marks were identified on 
transcription factors previously considered “master regulators” of Th cell differentiation, 
opening the possibility for diametrically opposed states of activation to alternately persist 
in a single clonal cell population (Lee, Turner et al. 2009; Wei, Wei et al. 2009).  
Immunomodulation in CLL 
Advances in disease pathogenesis and cytogenetics have vastly improved our 
biological understanding and therapeutic arsenal against CLL (Kay, Rai et al. 2006; 
Fulci, Chiaretti et al. 2007; Ouillette, Erba et al. 2008; Rassenti, Jain et al. 2008).  
Immunotherapeutic strategies that complement standard therapies, such as monoclonal 
antibodies, are part of current routine treatment, and next generation therapies are under 
investigation in CLL patients (Tam, O'Brien et al. 2008).  An additional advantage is that, 
since most patients are of advanced age, an immunotherapeutic approach may be more 
suitable than aggressive chemotherapeutic regimens (Ramsay, Johnson et al. 2008).  
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More notably, the emergence of novel immunomodulatory compounds has brought to 
light the importance of immunoregulation and stroma interactions in the management of 
CLL and has shown promising results, perhaps alleviating the tolerogenic phenotype that 
Common and immunologically relevant signaling molecules and cytokines are 
presented.  Cytokines are dived into group with either likely beneficial effects, 
probably beneficial effects, unknown effects, or likely negative effects from the 
perspective of immunotherapeutic intervention. 
Table 1: Cytokines involved in the development and progression of CLL.   
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characterizes this clinical malignancy (Chanan-Khan and Porter 2006; Kay, Rai et al. 
2006; Horna and Sotomayor 2007; Molica 2007; Rabinovich, Gabrilovich et al. 2007; 
Wierda and Kipps 2007; Ferrajoli, Lee et al. 2008).  On the forefront of these 
immunomodulatory compounds is lenalidomide, a derivative of thalidomide, which has 
been shown to repair the T-cell/CLL B-cell immunological synapse and increase natural 
killer cell and monocyte-mediated antibody-dependant cellular cytotoxicity (Ferrajoli, 
Lee et al. 2008; Ramsay, Johnson et al. 2008; Wu, Adams et al. 2008). Early clinical 
trials with lenalidomide have been shown to induce responses in refractory CLL patients 
(Chanan-Khan, Miller et al. 2006; Ferrajoli, Lee et al. 2008). 
CLL cytokine signaling 
Development of CLL is inextricably linked to the abrogation of normal cytokine 
loops in favor of signaling patterns, which promote proliferation or protection from 
apoptosis. Since the mature B cell is a known intermediary of a healthy immune 
response, CLL must manage the precarious induction of many pro-inflammatory 
cytokines through autocrine or juxtacrine mechanisms to obtain antiapoptotic signaling 
while simultaneously suppressing key cytokines that have the potential to promote anti-
tumor cytolytic responses. 
While the complex interplay between cytokines involved in CLL may be difficult 
to understand in its entirety, there are three signaling mediators that, if altered, could 
potentially drive the generation of an anti-CLL immune response: IL-2, IL-10, and IL-4.  
IL-2 is a known T-cell stimulatory cytokine that is selectively removed from the CLL 
microenvironment via upregulation of soluble and membrane bound IL-2 receptor (Table 
1) (Foa, Giovarelli et al. 1985; Fluckiger, Rossi et al. 1992; de Totero, Francia di Celle et 
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al. 1995; Mainou-Fowler, Copplestone et al. 1995).  IL-4 polarizes the T-helper 
compartment toward a Th2 response, simultaneously ensuring adequate CD4+ 
stimulation and proliferation (which feeds back in the form of CD40 stimulation) while 
maintaining an ineffective anti-CLL response (Dancescu, Rubio-Trujillo et al. 1992; 
Banchereau, Bidaud et al. 1993; Mainou-Fowler, Craig et al. 1995).  Moreover, IL-4 
serves as an antiapoptotic autocrine factor further exacerbating its effects (Howard, Farrar 
et al. 1982; Llorente, Mitjavila et al. 1990; Tangye and Raison 1997; Kay, Han et al. 
2001).  IL-10 functions to suppress immune responses and is known to stimulate T-
regulatory cell differentiation (Fiorentino, Zlotnik et al. 1991; Mosmann and Moore 
1991; Sher, Fiorentino et al. 1991; Del Prete, De Carli et al. 1993; Finke, Ternes et al. 
1993).  Although IL-10 is actively secreted by CLL cells, its effect on CLL itself is 
abrogated due to an ineffective intracellular signaling pathway, which ensures that the 
remaining healthy lymphocyte compartments are disproportionately inhibited (Levy and 
Brouet 1994; Sjoberg, Aguilar-Santelises et al. 1996; Fayad, Keating et al. 2001). 
Epigenetically regulated cancer antigens as immunotherapeutic targets for CLL 
Anti-tumor vaccines, also known as active immunotherapies, exemplify some of 
the newer targeted treatments being investigated in CLL (Dubovsky and McNeel 2007).  
Ideal antigen candidates would have applicability to a significant percent of patients, 
have expression restricted to the cancer and high immunogenicity, and would be essential 
for the survival of the CLL cell, thus restricting immune evasion (Krackhardt, Witzens et 
al. 2002).  One particular class of antigens, the cancer testis antigens (CTAs), has been 
investigated for these particular characteristics (Dubovsky, Albertini et al. 2007).  CTAs 
have expression restricted to immunologically “privileged” tissues (blood-testis barrier 
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and lacking surface expression of major histocompatability complex (MHC) molecule) 
such as germ cells but are often aberrantly expressed in tumor cells (Kowalik, Kurpisz et 
al. 1989; Scanlan, Simpson et al. 2004).  Their expression is thought to be induced by 
global genome hypomethylation, a well-known characteristic of cancer; it is this aberrant 
expression that presumably makes them available for immune recognition (De Smet, De 
Backer et al. 1996).  Indeed, recent studies have shown that hypomethylating agents such 
as 5-azacytidine and 5-aza-2’-deoxycytidine (5A2) can induce expression of CTAs, 
specifically in cancer cells, for prolonged periods of time, allowing for effective 
administration of CTA-based anti-tumor vaccines (Weber, Salgaller et al. 1994; Grunau, 
Sanchez et al. 2005; Guo, Hong et al. 2006; Coral, Sigalotti et al. 2007; Dubovsky and 
McNeel 2007).  Concordant results have shown that HDACi can have similar and 
synergistic effects, presumably due to the increased transcriptional availability of 
previously epigenetically silenced chromatin (Wischnewski, Pantel et al. 2006; Picard, 
Bergeron et al. 2007).  More importantly, however, HDACi treatment blocks a critical 
tumor immuno-evasive antigen silencing mechanism enabling the potential generation of 
a prolonged and effective T-cell response. 
 In CLL, an immunosuppressive phenotype enables the malignant B cell to evade 
immune detection (Krackhardt, Witzens et al. 2002; Scrivener, Goddard et al. 2003; 
Mellstedt and Choudhury 2006; Horna and Sotomayor 2007).  Novel strategies have been 
suggested that may supplant immunosuppression with appropriate cancer-antigen 
presentation leading to T-cell activation and killing (Khan, Magner et al. 2004; Khan, 
Magner et al. 2007; Wierda and Kipps 2007).  The hallmarks of such strategies hinge 
upon increasing the APC capacity of the CLL cell, reducing the levels of 
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immunosuppressive factors and generating a robust response against a non-tolerized 
cancer-specific antigen (Figure 3).  Recent studies have shown increased expression of 
MHC class I, class II, immunoproteosome subunits, peptide processing machinery, pro-
apoptotic molecules such as APO2L/TRAIL, and various costimulatory molecules after 
treatment with epigenetic modifiers, leading to enhanced cancer-specific immune 
responses (Borden 2007; Khan, Gregorie et al. 2008; Khan and Tomasi 2008). A role for 
epigenetic modifiers in the regulation of pro-inflammatory cytokines has also been shown 
(Sailhamer, Li et al. 2008).     
 The generation of a therapeutic and CLL-specific immune response is currently 
under active investigation.  Some of the more notable targeted proteins for vaccine 
approaches include specific idiotype immunoglobulin-derived peptides, survivin, KW-13, 
fibromodulin, MDM2, and telomerase (Harig, Witzens et al. 2001; Giannopoulos and 
Schmitt 2006; Kokhaei, Palma et al. 2007).  Other strategies have focused on the 
generation and adoptive transfer of CLL antigen-specific T lymphocytes (Foster, Brenner 
et al. 2008).  Additionally, adenoviral vector gene therapy using CD40-ligand (CD154) 
has been tested in early-phase clinical trials showing a reduction of disease burden in 
several patients (Trojan, Schultze et al. 2000; Krackhardt, Witzens et al. 2002; Schmidt, 
Schag et al. 2003; Mayr, Kofler et al. 2005; Giannopoulos and Schmitt 2006; Wierda and 
Kipps 2007).  These trials have served to reveal one unresolved consequence of CLL: the 
current antigenic repertoire has likely generated tolerance leading to a weak cytotoxic 
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Figure 3: Signaling interactions between CLL cells and T cells.  CLL cases vary 
however the most common signaling interactions are displayed in panel A.  Panel B 
shows CLL based T cell interactions which may result from an improved immunogenic 
profile, a goal of many therapeutic interventions currently under development. 
B 
A 
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response incapable of generating effective tumor cell clearance.  Experiments conducted 
by Guo et al. have shown that treatment of 4T1 tumor-bearing animals with such agents 
followed by adoptive transfer of P1A CTA-specific cytolytic lymphocytes (CTL) resulted 
in tumor-specific recognition and eradication(Guo, Hong et al. 2006).  These studies were 
very recently confirmed in a murine orthotopic glioma model using a prominent and 
highly immunogenic human CTA, NY-ESO-1 (Natsume, Wakabayashi et al. 2008). 
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Chapter Two: 
 
Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces 
expression of NXF2, an immunogenic cancer testis antigen 
Abstract 
Critical to success of active immunotherapy against cancer is the identification of 
immunologically recognized cancer-specific proteins with low tolerogenic potential. 
Cancer testis antigens (CTAs) in particular, fulfill this requirement as a result of their 
aberrant expression restricted to cancer cells and lack of expression in normal tissues 
bypassing tolerogenic mechanisms against self. Although CTAs have been extensively 
studied in solid malignancies little is known regarding their expression in chronic 
lymphocytic leukemia (CLL).  Using a two-pronged approach we evaluated the 
immunogenicity of 29 CTAs in 22 patients with CLL and correlated these results to RT-
PCR data from CLL cell lines and patient cells.  We identified IgG specific antibodies for 
one antigen, NXF2 and confirmed this response by ELISA and Western blot.  We found 
that treatment of CLL with 5-aza-2’-deoxycytidine can induce expression of NXF2 that 
lasted for several weeks after treatment.  Treatment also increased levels of MHC and 
costimulatory molecules (CD80, CD86, and CD40) necessary for antigen presentation.  
In addition, we identified other promising antigens which may have potential 
immunotherapeutic application.  Our findings suggest that NXF2 could be further 
pursued as an immunotherapeutic target in CLL, and that treatment with demethylating 
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agents could be exploited to specifically modulate CTA expression and effective antigen 
presentation in malignant B-cells. 
Results 
An IgG response specific to NXF2, a known cancer-testis antigen, was identified in CLL.    
In order to identify CTAs which may be recognized by the T-cell repertoire in the 
context of CLL we used high-throughput phage immunoblot, a technique we have 
previously described (Dubovsky, Albertini et al. 2007; Dubovsky and McNeel 2007).  In 
brief, lambda-phage encoding 29 known CTAs (Table 2) were spotted robotically in 
duplicate onto a bacterial lawn and overlaid with nitrocellulose membranes impregnated 
Table 2: Cancer-testis antigen panel 
 
The names and GenBank identifiers for each CTA chosen for analysis 
are shown.  In addition, the 5’ and 3’ primers used for the gene-specific 
RT-PCR amplifications are shown. 
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with IPGT to induce protein expression.  These membranes were then probed with sera 
from 22 patients with CLL (Table 3). 
 
Immunoreactive plaques specific for NXF2 were identified in CLL patient 9 (Figure 4A).  
This immunoreactivity was also found in serum collected from the same patient both 
three and nine months later, corroborating our initial data (Figures 4B and 4C).  These 
experiments were repeated in triplicate and all blots were found to be consistent.  To 
further examine this IgG reactivity we conducted an NXF2 specific ELISA on all 22 
Table 3: Clinical characteristics of CLL patients 
 
Serum and cells from CLL patients was used to identify 
immunologically recognized and inducible CTAs.  Patient 
Characteristics, Rai stage, cytogenetics, and prior treatments are 
shown.  “del” indicates a deletion of the indicated chromosomal arm 
or gene. 
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patients which confirmed a robust IgG response in patient 9 at both available timepoints 
(Figure 5A).  Using subisotype specific ELISA this NXF2 reactivity was found to be 
predominantly composed of subisotype IgG1 (Figure 5B).  As further confirmation of 
reactivity a Western blot was performed using serum from a subset of patients (CLL 9, 1, 
13, 2, 22, and 10) probing NXF2 transiently transfected 293T cell lysates which 
demonstrated that the IgG response was specific for NXF2 (Figure 5C).  
Expression of CTAs is induced by demethylating agents in CLL.    
In addition to finding particularly immunogenic CTAs we also sought to identify 
methylation inhibitor inducible CTAs in CLL.  To this end we designed transcript-
specific primers specific for each of the CTAs described in Table 2 and used this primer 
panel to profile CTA expression in a variety of CLL cells with or without 1µM 5A2 
treatment using RT-PCR.  The CLL cell lines MEC1, MEC2, and WaC3 were kindly 
Figure 4: High Throughput Phage Immunoblot indicates an IgG response to 
NXF2 
Patient number 9 had a detectable response to NXF2 (panel A).  Three months later 
on a return visit for further observation the same patient displayed reactivity to NXF2 
once again, confirming the first occurrence (panel B).  Reactivity to NXF2 was also 
seen at a six month observation point for patient 9 (panel C).  Immunoreactive spots 
are determined by visually comparing them with the negative “-” and positive control 
“+” spots on each filter.  Of the 22 patients screened NXF2 was the only reactive CTA 
discovered. 
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provided to us by Dr. John Byrd at the Ohio State University Medical Center and are 
further described in (Wendel-Hansen, Sallstrom et al. 1994; Stacchini, Aragno et al. 
1999).  Using these cell lines we identified multiple genes which were either induced de 
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novo, were significantly upregulated, or were constitutively upregulated (Figure 7A).  Of 
the 29 CTAs tested expression of NY-SAR-35, XAGE-1, GAGE-2, 7, and 4, LAGE-1, 
NXF2, NY-ESO-1, and SSX2 was induced de novo after treatment with 5A2.  Expression 
Figure 5: ELISA and Western Blot results confirm IgG response to NXF2 and 
identify major subisotype 
 Sera from patients with CLL were subjected to ELISA using GST tagged NXF2 
purified protein (panel A).  The NXF2-specific antibody response is primarily of the 
IgG1 subisotype (panel B).  To eliminate the possibility of potential GST-specific 
reactivity serum from a subset of patients, including the reactive patient #9, were used 
to probe NXF2 transient transfection Lysates (positive = anti-NXF2 polyclonal 
antibody) (negative = no loaded protein) (Panel C).  Patient 9 donated serum on two 
separate occasions delineated by 9a and 9b in all ELISA data. 
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of MAGE-A1, A3, A4, and B2, SSX1, and 4, TPX-1, and FATE-1 was significantly 
upregulated by treatment with 1µM 5A2.  Additionally, we found that mRNA levels of 
LIP1, MAD-CT-1 and 2, SPA17, MAGE-B1 and E1, PAGE-5, and SPAN-XC were 
constitutively expressed. 
To confirm the relevance of our in-vitro cell culture models we examined the 
tumor CTA expression profile of three representative CLL patients 3, 9, and 13 using 
total RNA from purified CLL cells (>90% purity) (Figure 7B).  We found that CTA 
expression was extremely similar to that of the cell lines.  From these samples we found 
that NY-SAR-35 and XAGE-1 are expressed at low levels in some CLL patients.  In one 
final layer of stringency we tested the CTA expression in cell lines from other similar B-
Cell lymphoproliferative disorders (Figure 6).  In this screening the only consistently 
Figure 6: Analysis of B-Cell leukemia confirms inducibility of certain CTAs. 
As additional confirmation of inducibility the B-Cell leukemia lines RAJI, SKLY-16, 
and 697 were analyzed for CTA expression pre and post treatment with 1µM 5A2.  
CTA inducibility was found to be similar to that of CLL. 
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inducible CTA was NXF2, although other CTAs were inducible in particular cell lines. 
 
Of the three classes of leukemia CTAs (inducible de novo, upregulated, and 
constitutively expressed) currently the most attractive class from the prospective of CLL 
immunotherapy is those CTAs which are not normally expressed, but upon treatment 
with 5A2 can be strongly induced de novo.  This modulated expression may help to avoid 
many of the tolerogenic mechanisms utilized by CLL, as will be discussed further.  Thus 
far, NXF2 satisfies both characteristics of our initial investigation, demonstratable 
immunogenicity and selective inducibility. 
NXF2 is a naïve and selectively inducible CLL specific antigen.   
Figure 7: RT-PCR reveals novel constitutively expressed, inducible, and 
upregulated CTAs in CLL. 
Three cell lines, MEC1, MEC2, and WaC3 were analyzed via transcript-specific RT-
PCR for mRNA expression of CTAs pre and post treatment with 1µM 5A2 (panel A).  
To ensure that CTA expression patterns in the CLL cell lines are representative CLL 
cells from patients 3, 9, and 13 were analyzed for basal CTA expression (panel B).  
Testis cDNA was analyzed as a positive control as well as a no-RNA transcript 
negative control, confirming the identity of the amplified products. 
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While NXF2 has demonstrated expression in CLL cell lines after treatment with 
5A2, aside from its initial discovery, there is scant information as to the expression in the 
majority of human tissues(Loriot, Boon et al. 2003). Consequently, we evaluated the 
Oncomine micro-array database, which contains data from over 20,000 human 
microarray studies for mRNA expression of NXF2 in normal tissues.  In a panel of 40 
normal tissues NXF2 was only significantly upregulated in the testis, as expected (Figure 
8).  
To confirm that NXF2 has no basal mRNA expression in CLL prior to treatment 
with methylation inhibitors we examined the RNA from 10 CLL patients at various 
stages in disease progression and found no detectable transcripts (data not shown).  Since 
it is possible that the protein has a long half life after initial mRNA expression we tested 
several CLL patients by western blot and again found no expression of NXF2 (data not 
shown).  Taken together, these results indicate that the average CLL patient is likely 
naïve to the NXF2 antigen prior to treatment with demethylating agents. 
Given that primary CLL cells do not proliferate ex-vivo and thus do not 
incorporate 5A2 into their DNA it has previously been very difficult to study the 
demethylating effects of such nucleotide analogs outside of in-vivo or cell culture 
systems.  Recent research into the critical signaling networks between CLL cells and their 
stromal environment has led to the development of a CD40L expressing murine fibroblast 
feeder cell line which, in conjunction with IL-4, induces limited proliferation in some 
human CLL primary samples.  Using this system we characterized the epigenetic changes 
to the CTA expression pattern in CLL patient 9.  As shown in figure 9, we saw a marked 
increase in FATE-1, MAGE-A4, and MAGE-A8 transcription and a de-novo induction of 
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XAGE, GAGE-4, 2, and 7, SSX-1 and 2, PAGE-1, and NXF2 transcripts.  These data 
served to confirm our initial antigen identification and to demonstrate NXF2 inducibility 
in primary cells.  
Immunogenic CTA expression can be modulated for a possible immunotherapeutic 
approach.   
Since any potential CTA based immunotherapy would require antigen expression 
to extend beyond the initial treatment period we wanted to examine the stability of 
antigen expression in the three CLL cell lines after 5A2 treatment.  Cells were treated 
with 1µM 5A2 for 72 hours and then washed and cultured with serum-supplemented 
media only for up to 20 days.  Cells were harvested at various timepoints after washout 
and assessed for NXF2 mRNA by qRT-PCR.  As shown in Figure 10A, in the MEC2 cell 
Figure 8: NXF2 expression is primarily restricted to the testis among normal 
tissues. 
The Oncomine database, containing cancer gene expression profiles from over 20,000 
microarrays (Rhodes, Kalyana-Sundaram et al. 2007) (available at 
www.oncomine.org), was queried for the presence of NXF2 mRNA among different 
normal tissue sets.  Shown are the relative expression units of NXF2 among 40 normal 
tissues including testis with mean and standard error indicated (n ranges from 3 to 13). 
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line treatment induced a sharp increase in NXF2 expression (25 fold) which trailed off 
slowly, yet still not completely by day 20.  Surprisingly, the sister MEC1 cell line had 
different NXF2 expression kinetics indicating that peak expression (200 fold) came long 
after 5A2 treatment (around day 10) and tapered off, yet still not completely, by day 20.  
The WaC3 cell line upregulated NXF2 to an extremely high level (450 fold), relative to 
MEC1/2.  This high level of expression did not significantly change throughout the 
experiment, but the cell line was unable to survive beyond day 10 indicating a residual 
cytotoxicity induced by the 5A2 treatment. 
In addition to NXF2 our screening has unveiled other promising antigens which 
have proven to be immunogenic in other forms of cancer.  Among these antigens NY-
ESO-1, SSX1, SSX2, MAGE-A1, and MAGE-A4 have received attention because they 
are expressed in a variety of common tumor types.  Given that these antigens have shown 
exceptional promise we decided to further characterize their expression in CLL after 5A2 
treatment.  Using the WaC3 cell line we found that mRNA expression levels for NY-
ESO-1, MAGE-A1, and MAGE-A4 increased by 2.5 to 7.5 fold for each of these 
antigens after treatment with 5A2 (Figure 10B).  Moreover, we found that both SSX1 and 
Figure 9: NXF2 is among a variety of inducible CTAs in primary human CLL 
treated with 5-aza-2’-deoxycytidine. 
CLL cells cultured with IL-4 atop an irradiated CD40L expressing murine fibroblast 
stromal layer were analyzed via transcript-specific RT-PCR for mRNA expression of 
CTAs with and without 1µM 5A2 treatment.  Testis cDNA was analyzed as a positive 
control as well as a no-RNA transcript negative control, confirming the identity of the 
amplified products (controls displayed in previous figure). 
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SSX2 were highly upregulated in all three cell lines after 5A2 treatment (Figure 10C).  
These data indicate that in CLL there are proven antigenic CTAs expressed at high levels 
after 5A2 treatment further implying the applicability of immunotherapy. 
Demethylation restores effective antigen presentation characteristics in CLL cell line.  
Given that the majority of gene expression changes involved in the initiation of 
antigen presentation are epigenetically regulated we wanted to investigate the role of 5A2 
on the antigen presenting cell (APC) capacity of the CLL cell.  Using the representative 
CLL cell line MEC1 we analyzed the changes in MHC class I (HLA-A, B, C) MHC class 
Figure 10: NXF2 expression in CLL cell lines can be modulated by treatment 
with the DNA methylation inhibitor 5-aza-2’-deoxycytidine. 
CLL cell lines (white bars = MEC1, grey bars = MEC2, black bars = WaC3) were 
cultured for 72hr in the presence of 1µM 5A2.  Panel A: Cells were washed and then 
continued to be cultured in the absence of 5A2.  Cells were then collected on days 3, 
5, 10, and 20 (WaC3 was unable to be cultured past day 10) and RNA was subjected 
to NXF2 transcript-specific qRT-PCR.  Panel B: RNA from the WaC3 cell line was 
subjected to qRT-PCR specific for NY-ESO-1, MAGE-A4, and MAGE-A1.  Panel C: 
RNA from all CLL lines was subjected to qRT-PCR for SSX2 and SSX1 indicating 
upregulation of mRNA expression in the presence of 5A2.  The fold increase in gene 
expression, compared with untreated cells and relative to actin, was determined using 
the 2-∆∆CT method(Pfaffl 2001).  The data shown is the mean and standard deviation of 
three independent qRT-PCR experiments. 
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II (HLA-DR) CD40, CD86, and CD80 by flow cytometry.  As shown in Figure 11A we 
Figure 11: Demethylation restores effective antigen presentation characteristics 
in a CLL cells. 
The representative CLL cell line MEC1, or human primary CLL cells cultured using 
IL-4 and an irradiated CD40L transfected fibroblast feeder layer, were cultured for 
72hr in the presence of 1µM 5A2 and analyzed by flow cytometry for the surface 
expression of MHC class I molecules (HLA-A, B, C) MHC class II molecule (HLA-
DR) and the APC costimulatory molecules (CD80, CD86, and CD40) as compared to 
basal levels under an identical culture system without 5A2 (untreated) (panel A).  The 
72 hour proliferative capacity (and likewise 5A2 uptake capacity) is demonstrated in 
CFSE labeled primary human CLL cells in a separate experiment using only serum 
supplemented RPMI (untreated), the CD40L fibroblast stromal layer + IL-4, or the 
CD40L fibroblast stromal layer + IL-4 + 1µM 5A2 (panel B).  Data shows that 5A2 
treated cells (black histograms) upregulate expression of all five molecules when 
compared to basal expression (grey histograms) and that this trend is mimicked by 
primary human CLL cells despite only a small percentage of cells incorporating the 
drug in the in-vitro system. 
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found that both MHC class I and class II molecules were upregulated after treatment.  
Furthermore, the costimulatory molecules CD40, CD80, and CD86 were also 
upregulated.  These effects were mimicked by in-vitro cultured primary CLL cells, which 
were induced to proliferate in the presence of 5A2 using the CD40L expressing murine 
fibroblasts along with IL-4.  As an independent CFSE staining experiment demonstrated 
our in-vitro fibroblast culture system induced proliferation in only 1% of the cells over 
the 72 hour treatment, thus our analysis represents a mixture of treated and untreated 
primary cells (Figure 11B).  These data suggest that treatment with 5A2 may aid in 
effective cancer-testis antigen presentation by the CLL cell to both CD4 and CD8 T-cells. 
Discussion 
Our goal has been to identify potential CTA targets that may be pursued in the 
development of future immunotherapies.  In previous reports we have used similar high-
throughput antibody screening methods to identify antigens in both prostate cancer and 
melanoma (Dubovsky, Albertini et al. 2007; Dubovsky and McNeel 2007).  One critical 
difference is the two-pronged approach utilized.  Hematologic malignancies such as CLL 
provide unparalleled access to tumor specimens via a simple blood draw, something 
uncommon to most solid tumors which require access to small biopsy or post surgical 
resection specimens for mRNA or protein analysis.  Our study has taken full advantage of 
this characteristic to complement our analysis.  In previous reports we were only able to 
identify a small number of candidate antigens.  We assumed that this was due to the small 
number of sera samples evaluated and because a smaller fraction of subjects would be 
expected to have an immune response to a particular antigen, even if expressed by a 
particular tumor (Hoeppner, Dubovsky et al. 2006).  In the current report we started out 
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with an even smaller number of sera samples, making this task even more difficult.  
Moreover, recent landmark efforts in epigenetic profiling have uncovered the methylation 
status of the CLL genome revealing relatively high and heterogenic levels of global CpG 
methylation(Melki, Vincent et al. 2000; Melki and Clark 2002; Rush, Raval et al. 2004).  
In light of this evidence, it is conceivable that a variety of immunogenic proteins, 
including CTAs, are silenced and thus naïve to the immune system(Plass, Byrd et al. 
2007). 
Despite these hurdles we have managed to identify NXF2 as an immunogenic 
CTA in a CLL patient.  We have confirmed this antibody response using both ELISA and 
western blot.  Interestingly, we were unable to confirm expression in any single patient 
with CLL, including patient 9 (the CLL patient with an antibody response to NXF2).  It is 
highly likely that early progression and evolution of CLL is fashioned by immunoediting, 
the repeated evasion of immune recognition(Dunn, Bruce et al. 2002; Dhodapkar, 
Krasovsky et al. 2003; Dunn, Old et al. 2004).  Although, it is still unclear as to the exact 
antigen milieu which shapes CLL since it is difficult to study the complete progression of 
the disease (starting at the initial transforming event) in any single patient, it is likely that 
antibody responses to these antigens may still be detectable since they persist years after 
antigen stimulation.  It is postulated that these antigens already have a proven capacity to 
eliminate CLL clones, but their non obligate nature has led to their eventual silencing.  
An additional explanation would be that patient 9 has a separate undiagnosed malignant 
condition which expresses NXF2 aberrantly and this served to induce this immune 
response.  However, standard screening procedures for patients over 50 were done with 
no evidence of any other malignant condition.  Patient 9 has an indolent CLL 
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characterized by the presence of 13q14 del., ZAP70 negative, IgVH mutated, but CD38 
positive.  Interestingly, patient 9 has a polyclonal IgG increase (2.1g/dl compared to a 
1.5g/dl for the upper limit of normal).  This condition may have increased the likelihood 
of identifying a normally low-level antigen response in CLL, a disease which more 
commonly causes hypogammaglobulinemia.  Nevertheless, since a specific IgG response 
requires CD4+ T-cell help, our discovery gives us a glimpse of the functioning T-cell 
repertoire in the context of CLL. 
Additionally, our study provides the first account of an in-vitro method 
appropriate for treatment with DNA demethylating agents.  The CD40L expressing 
fibroblast stromal cell system has made it possible to isolate the epigenetic changes 
which occur in CLL upon treatment with such inhibitors(Wheeler and Gordon 1996; 
Jacob, Pound et al. 1998; Willimott, Baou et al. 2007).  Furthermore, this being the first 
murine based feeder cell system provides an obvious advantage when using PCR specific 
for a rare-expressed human gene.  In our study it facilitated confirmation of NXF2 
inducibility and the resulting immunophenotype of the 5A2 treated primary CLL cells.  
One caveat to this culture system is that it is still impossible to differentiate the 
expression and immunophenotype the specific fraction of CLL cells who have 
incorporated the drug, leading to an observed dilution of the effects of 5A2. 
NXF2 was first identified by homology to known murine spermatogonally expressed 
genes(Wang, McCarrey et al. 2001; Loriot, Boon et al. 2003).  Fortunately, Loriot et. al. 
had the foresight to attempt modulation of this gene using 5-aza-2’-deoxycytidine at the 
time of discovery, a result which has shaped our current investigation.  Although little 
attention has been paid to its antigenicity a few groups have investigated its function as 
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an mRNA exporter, interactions with cytoplasmic motor proteins, and role in male 
infertility(Takano, Miki et al. 2007).  It has been hypothesized that NXF2 may have 
multiple roles critical to the meiotic process(Wang and Pan 2007).  Conceivably, these 
roles would have wide reaching benefits to the pre-malignant B-cell including the 
independent segregation of undesired chromosomes leading to anuploidy and the 
recombination of genetic material leading to translocations and deletions(Simpson, 
Caballero et al. 2005).  Moreover, Wang and co-workers have shown that expression of 
NXF2 is strictly temporally regulated in the early spermatocyte.  This expression 
characteristic may also be true in the early development of leukemia. 
In our study we characterized the spontaneous immune response to NXF2 as 
predominantly IgG1 which is consistent with the generation of a Th2 immune response 
which does not necessitate CD8+ CTL activation.  Although the ideal antigen would 
spontaneously generate a Th1 or Th17 response, it is not entirely unexpected that a 
patient with CLL would generate such a response given that Rossmann and colleagues 
have shown an association between CLL and T-cell production of Th2 bias cytokines  
such as IL-4(Rossmann, Lewin et al. 2002).  This effect will need to be overcome in 
order for T-Cell based vaccines to be truly effective.  However, emerging evidence 
implicates a CD4+ T-Cell response in significant, rapid, and antigen specific cytotoxic 
responses in CLL and CTA (NY-ESO-1) vaccine trials(Chu, Deforce et al. 2002; Hunder, 
Wallen et al. 2008). 
We have shown here that NXF2 mRNA can be upregulated for extended periods 
of time after treatment with the methylation inhibitor 5-aza-2’-deoxycytidine.  In prior 
studies we and others have found that transient treatment with 5A2 was able to induce 
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prolonged and cancer restricted expression of CTAs and based on our results it appears as 
though this is true for CLL as well.  It has been postulated that this is due to selective 
degradation of the corrective enzyme, DNA methyltransferase I (DNMT1) combined 
with an inability to upregulate expression of this critical gene post-treatment.  However, 
in our experience mRNA expression of DNMT1 mRNA seems unchanged in both normal 
and cancer cells lending evidence to the contrary(Dubovsky and McNeel 2007).  
Nevertheless, this characteristic will likely be essential to the generation of an effective 
immune response since CTAs have not proven to be obligate antigens (required for 
continued cancer survival or proliferation) their cancer specific expression must be forced 
in order to prevent tumor escape variants from causing relapse. 
In addition to NXF2, our study identified multiple novel CLL CTAs which may 
have varied application for an immunotherapeutic treatment of CLL.  Classical antigens, 
antigens which are expressed constitutively in cancer cells, such as LIP1, MAD-CT-1 and 
2, SPA17, MAGE-B1 and E1, PAGE-5, and SPAN-XC as well as those antigens with 
lower level expression in a subset of CLL lines such as MAGE-A1, A3, A4, and B2, 
SSX1 and 4, TPX-1, and FATE-1, have the potential to generate a robust immune 
response.  In similar fashion, NY-ESO-1 and the  MAGE family of CTAs are highly 
expressed in many tumor types and have shown promising results in early phase vaccine 
trials(Jager, Gnjatic et al. 2000; Brichard and Lejeune 2008).  Our results in both cell 
lines and primary CLL indicate that these antigens may also be effective targets in CLL. 
In CLL an immunosuppressive phenotype enables the B-cell to evade immune 
detection(Krackhardt, Witzens et al. 2002; Horna and Sotomayor 2007; Wierda and 
Kipps 2007).  Wierda and Kipps recently reviewed this topic putting together multiple 
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strategies which have shown promising results.  In the current study we show that surface 
expression of necessary costimulatory molecules as well as MHC class I and II can be 
increased on CLL cells using 5A2.  Studies conducted by Coral et. al. have shown similar 
results although never in a tumor arising from a semi-professional APC(Coral, Sigalotti 
et al. 1999).  It is conceivable this effect on a cell with antigen presenting capacity can 
aid in the presentation of CLL peptides via MHC “signal 1” and the costimulation of T-
cells recognizing such peptides “signal 2”. 
One unresolved consequence of CLL is that the current antigenic repertoire has 
likely generated tolerance.  Theoretically this can be avoided by vaccinating towards an 
inducible de novo antigen which is not yet expressed followed by induction of antigen 
expression using hypomethylating agents.  Similar experiments conducted by Guo et. al. 
have shown that treatment of 4T1 tumor-bearing animals with 5-aza-2’-deoxycytidine, 
followed by adoptive transfer of P1A CTA-specific cytolytic lymphocytes (CTL), 
resulted in tumor-specific recognition and eradication(Guo, Hong et al. 2006).  
In the current study we have utilized a two-pronged approach to evaluate the 
immunogenicity of 29 CTAs in 22 patients with CLL and correlate these results to RT-
PCR data from CLL cell lines and patient cells enumerating antigens which are both 
immunogenic and specific for CLL.  We identified IgG specific for one novel CLL 
cancer-testis antigen NXF2 and confirmed this response by ELISA and western blot.  In 
addition, we confirmed that treatment of CLL with 5-aza-2’-deoxycytidine can induce 
expression of NXF2 for weeks post treatment.  Treatment also increases levels of MHC 
and costimulatory molecules necessary for antigen presentation.  In addition, RT-PCR 
results identified other promising antigens which may have potential immunotherapeutic 
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application.  Our findings suggest that NXF2 could be further pursued as an 
immunotherapeutic target in CLL, and that treatment with demethylating agents could be 
exploited to specifically modulate antigen expression in a potential vaccinate-induce 
strategy. 
Materials and methods 
Subject Populations 
Sera and peripheral blood mononuclear cells (PBMCs) were obtained from 22 
patients with CLL (16 males and 6 females, mean age 62 years, range 37-77 years).  Of 
these subjects, 10 had 13q deletions, 3 had 17p deletions, 4 had trisomy 12, and 7 had 
normal cytogenetics.  In total, 7 patients had prior definitive treatment (Table 3).  Rai 
stage for the 22 patients was: 5 patients = 0, 13 patients = I, 1 patient = II, 3 patients = IV.  
All subjects gave written institutional review board (IRB)-approved informed consent for 
their blood products to be used for immunological research.  Blood was collected at H. 
Lee Moffitt Cancer Center (Tampa, FL), and sera were stored in aliquots at -80°C until 
used. 
Phage Immunoblot Analysis 
We have previously reported the construction of a panel of lambda phage 
encoding 29 cancer-testis antigens(Dubovsky, Albertini et al. 2007).  Analysis of this 
panel was conducted similarly to what we have previously reported (Dubovsky, Albertini 
et al. 2007; Dubovsky and McNeel 2007).  In brief, XL-1 blue MRF E. coli were grown 
overnight, collected by centrifugation, resuspended in 10mM MgSO4, and poured in top 
agarose (LB broth/10mM MgSO4/0.2% maltose/0.7% agarose) over LB agar in Omniwell 
plates (Nunc, Rochester, NY).  Phage encoding individual (9,000 pfu) CTA’s were then 
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spotted in replicates onto multiple bacterial agar lawns using a liquid handling robot 
(Biomek FX, Beckman, Fullerton, CA).  Spotted plates were allowed to sit undisturbed 
for 15 minutes and then overlaid with nitrocellulose membranes impregnated with 10mM 
IPTG.  Plates were incubated overnight at 37°C.  The next day, filters were washed, 
blocked with TBS (50mM Tris pH 7.2, 100mM NaCL) + 1%BSA (bovine serum 
albumin), and then probed overnight with human serum diluted 1:100 in blocking 
solution.  Subsequently, the membranes were washed, and human IgG was detected with 
an alkaline phosphatase-conjugated anti-human IgG detection antibody (Sigma, St. Louis, 
MO).  The filters were washed again and then developed with 0.3mg/ml nitro-blue 
tetrazolium chloride (NBT) + 0.15mg/ml 5-bromo-4-chloro-3’-indolyphosphate p-
toluidine salt (BCIP).  After development, filters were washed with deionized water and 
immunoreactive plaques were recorded for each filter by visual comparison with internal 
positive (phage encoding human IgG) and negative (empty phage encoding beta-
galactosidase) control plaques. 
Enzyme-Linked Immunosorbent Assay (ELISA) 
Ninety-six-well high binding plates (Corning, Corning, NY) were coated with 
purified Glutathione-S-Transferase linked NXF2 protein (Novus Biologicals, Littleton, 
CO) at 2ug/ml or purified human IgG (Sigma) titrations starting at 2ug/ml in 50mM 
sodium carbonate buffer (pH 9.6) overnight at 4°C.  After blocking for 2 hours at room 
temperature with phosphate buffered saline (PBS)/1% bovine serum albumin (BSA) 
wells were filled with dilutions of CLL patient serum in blocking solution (1:25, 1:50, 
1:100) and were incubated overnight at 4°C.  To detect autoantibody plates were washed 
three times with PBS/0.1% Tween-20 and anti-human IgG HRP antibody (GE-
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biosciences, Piscataway, NJ) was added at 1:1000 in blocking buffer.  Alternatively, for 
the IgG subisotype ELISAs, biotinylated anti-IgG1, -IgG2, -IgG3, or -IgG4 (Sigma) were 
used followed by HRP-labeled streptavidin (GE-biosciences).  After a three-wash step 
reactivity was measured using TMB substrate (KPL, Gaithersburg, MD) according to 
manufacturer instructions. 
Western Blot 
Lysates from NXF2 transiently transfected 293T cells were mixed 1:2 with 2X 
sodium dodecyl sulfate (SDS) Laemmli’s loading buffer (0.04M Tris, pH 6.8, 12% 
glycerol, 1.25% SDS, 3% β-mercaptoethanol, 0.06% bromophenol blue) and boiled for 5 
minutes at 100°C.  Proteins were then resolved on 10% SDS-Polyacrylamide gels and 
were electrophoretically transferred to nitrocellulose membranes.  Membranes were then 
probed using standard immunoblot techniques; with CLL patient sera diluted 1:100 in 
blocking solution or NXF2-specific antibodies (Novus Biologicals).  Final detection was 
done using ECL chemiluminescent substrate (Perkin Elmer, Boston, MA) and 
autoradiography film. 
Primary Cell Culture 
CLL cells were isolated from peripheral blood by density gradient centrifugation, 
washed, and resuspended at 3X106 in RPMI 1640 medium (Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal calf serum and 20ng/ml recombinant human IL-4 (RDI, 
Concord, MA).  Isolated CLL cells (>95% purity) were cultured in 25cm2 tissue culture 
flasks atop an adherent bed of irradiated (30Gy) CD40L (CD154) expressing murine 
fibroblast L-cells.  Cultures were maintained in the presence or absence of 1µM 5A2 for 
72 hours and were subsequently assayed via RT-PCR or flow cytometry. 
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Reverse Transcriptase-PCR (RT-PCR) 
Total RNA was prepared from centrifugally pelleted cell cultures (RNeasy mini 
columns and RNAse free DNAse, Qiagen, Valencia, CA) or was commercially obtained 
(BioChain, Hayward, CA).  RT-PCR reactions were conducted using the Qiagen one-step 
RT-PCR kit (Qiagen) with transcript-specific primers (Table 2) and total RNA from 
various B-Cell leukemia and CLL cell lines as templates (generous gifs from Dr. John 
Byrd at Ohio State University).  RT-PCR amplification reactions were resolved on 2% 
agarose gels and the size of the amplified transcript confirmed by comparison with DNA 
size markers (GelPilot 1Kb Plus Ladder, Qiagen). 
Quantitative Reverse Transcriptase-PCR (qRT-PCR) 
Cell lines were cultured in the presence or absence of 5-aza-2’deoxycytidine 
(5A2) at 1µM.  After 72 hours of culture, cells were washed multiple times with PBS and 
re-cultured in medium without 5A2 for up to 20 days.  Total RNA obtained from these 
cultured cell lines (RNeasy mini columns, Qiagen) was analyzed for β-actin and NXF2 
RNA by qRT-PCR using a manufacturer’s standard protocol (iScript RT-PCR with 
SYBR green, BioRad, Hercules, CA) and NXF2, MAGE-A3, MAGE-A4, SSX1, SSX-2, 
or β-actin-specific gene primers (Table 2, and β-actin-5’ 
TCATGAAGTGTGACGTTGACATCCGT, β-actin-3’ 
CTTAGAAGCATTTGCGGTGCACGATG).  Fluorescent amplicon signatures and cycle 
of transmittance values (CT) were obtained using a BioRad MyCycler and its associated 
software, MyIQ v1.0 (BioRad).  Fold changes in NXF2 expression relative to actin were 
calculated according to the 2-∆∆CT method previously described(Pfaffl 2001).  The 
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reported fold change in gene expression was determined from two independent qRT-PCR 
measurements performed at different times. 
Flow Cytometry 
Flow cytometric analysis of CLL cell lines was performed using fluorochrome-
labeled monoclonal antibodies (mAbs; anti-HLA-A,B,C, -HLA-DR, -CD40, -CD80, -
CD86, -CD19, and –CD20, Becton Dickinson, San Jose, CA and eBiosciences, San 
Diego, CA)  and the vitality die 4',6-diamidino-2-phenylindole (DAPI, Sigma).  For 
CFDA-SE (CFSE) staining cells were resuspended in 0.5µM CFSE (Invitrogen) in RPMI 
medium for 15 minutes at 37°C followed by a wash and an additional 30 minute 
incubation in serum supplemented medium prior to resuspension in culture medium.  
Data was acquired on an LSRII cytometer (Beckman Coulter), and analyzed with FlowJo 
software (Tree Star, Ashland, OR). 
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Chapter Three: 
Restoring the Functional Immunogenicity of Chronic Lymphocytic 
Leukemia Using Epigenetic Modifiers 
Abstract 
Chronic lymphocytic leukemia (CLL) is a malignancy arising from immune cells 
(B-lymphocytes) endowed with intrinsic antigen-presenting capabilities.  Such a function 
however is lost during malignant transformation and CLL cells are well known for their 
inability to process and present antigens to the T-cell arm of the immune system.  Instead, 
malignant CLL cells elicit a vast array of immune regulatory mechanisms conducive to 
T-cell dysfunction and immunosupression.  Previously, we have shown that treatment of 
CLL cells with the demethylating agent 5-aza-2’-deoxycytidine unleashed target antigen 
expression.  Here we show for the first time that combining two epigenetic modifiers, 5-
aza-2’-deoxycytidine and the histone deacetylase inhibitor LAQ824 effectively restores 
the immunogenicity of CLL cell lines as well as primary cells obtained from CLL 
patients.  Indeed, such a combination induces the expression of novel and highly 
antigenic cancer testis antigens (CTAs) and co-stimulatory molecules.  These changes 
facilitate the formation of robust supramolecular activation complexes (SMAC) between 
CLL cells and responder T-cells leading to intracellular signaling, lytic granule 
mobilization, and polarization of functional and relevant T-cell responses.  This cascade 
of T-cell activating events triggered by CLL cells with restored APC function, points to 
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combined epigenetic modifier treatment as a potential immunotherapeutic strategy for 
CLL patients. 
Results 
Epigenetic modifiers synergistically induce CTA expression in CLL cells. 
Our prior studies in CLL indicate that 5A2 treatment alone is capable of inducing 
the expression of highly antigenic CTAs(Dubovsky, McNeel et al. 2009).  Given this 
prior knowledge we wanted to examine the combined effect of 5A2 and histone 
deacetylase inhibitors in this regard.  
Prior to initiating experimentation, we first wanted to confirm that our epigenetic 
modifiers were capable of altering chromatin structure in a CLL cell line.  Previous 
studies have documented acetylation changes at conserved interferon gamma distal 
regulatory elements (Shnyreva, Weaver et al. 2004; Schoenborn and Wilson 2007).  To 
Figure 12: 5A2 and LAQ treatment of a CLL cell line induces histone acetylation 
changes at the chromatin level.  Chromatin immunoprecipitation experiments using 
acetylated Histone–H4 specific antibody carried out with MEC1 CLL cells untreated, 
treated with 1uM 5A2, 25nM LAQ, or both 1uM 5A2 and 25nM LAQ were quantified 
via Q-PCR and normalized to input controls.  Primers specific for a known distal 
regulatory region of the IFN-γ gene were used as a marker for effective rearrangement 
of chromatin acetylation patterns. Reactions were repeated in triplicate, error bars 
display standard deviation and significance (p<0.05) above the untreated condition is 
indicated by an asterisk. 
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confirm the activity of 5A2, LAQ, and 5A2/LAQ in MEC1 cells, we profiled the 
acetylation changes occurring at the regulatory CNS+18 locus of the IFNG gene.  As 
expected, our results demonstrated increased H4 acetylation in treated MEC1 cells 
indicating that both drugs were capable altering chromatin structure in a CLL cell line 
(Figure 12). 
We therefore compared the mRNA expression pattern of 29 known CTAs 
between our CLL cell lines WaC3, MEC1, and MEC2 and primary CLL samples by RT-
PCR.  As shown in Figure 13A there is diverse low-level expression of multiple CTAs 
including SPANXC, MAD-CT-1 and -2, LIP1, SPA-17, and many members of the 
MAGE CTA family.  Additionally, mRNA expression of SSX-1, -2, and -4, NY-SAR-35, 
GAGE-2, -4, and -7, XAGE-1, NXF2, LAGE-1, NY-ESO-1, TPX-1, FATE-1, ADAM-2, 
and TSP50 was extremely low or nonexistent in the majority of CLL samples and the 
CLL cell lines.  The observed CTA expression profile indicated that interpatient 
expression patterns are somewhat variable.  Nevertheless, our CLL cell lines accurately 
mirror the CTA expression trends seen in ten random patients with primary CLL making 
them valuable tools for in-vitro studies. 
We next sought to improve upon basal expression patterns by treating our CLL 
cell lines with 5A2, LAQ, or a combination treatment of both 5A2 and LAQ (Figure 
13B).  mRNA expression data from these studies indicated that while both 5A2 and LAQ 
were capable of inducing the expression of varied CTAs only the combination treatment 
was capable of eliciting robust expression amongst virtually all of the CTAs tested 
including SSX-1, -2, and -4, NY-SAR-35, GAGE-2, and -7, XAGE-1, NXF2, LAGE-1, 
NY-ESO-1, TPX-1, FATE-1, ADAM-2, and TSP50, antigens which were nonexistent 
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prior to treatment.  While these results indicate a cooperative nature between the two 
Figure 13: Cancer-testis antigen expression is significantly increased in CLL 
after treatment with combined epigenetic modifiers.  RT-PCR results using 
transcript-specific primers for each of 29 known CTAs shows that our CLL cell lines 
mimic basal expression when compared to primary CLL (Panel A). Normal Human 
testis cDNA serves as a positive control and a mixture of PBMC RNA from 10 
healthy blood donors serves as the negative control.  A progressive increase in CTA 
expression can be seen in all cell lines after treatment with either 1uM 5-aza-
2’deoxycytidine (5A2) or 25nM LAQ824 (LAQ) with the greatest levels achieved 
after combined treatment with both inhibitors (Panel B).  Similar results were 
achieved utilizing primary CLL samples cultured on CD40L expressing murine 
fibroblasts and treated with the same concentrations of 5A2 and LAQ (Panel C).  
Experiments conducted on cell lines were repeated three times and experiments 
conducted on patient samples were repeated at least two times with similar results. 
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drugs we also observed synergistic activity with respect to certain CTAs, namely NY-
ESO-1, FATE-1, TPX-1, PAGE-1, and TSP-50. 
Given that primary CLL cells do not proliferate ex-vivo and thus do not 
incorporate 5A2 into their DNA it has previously been challenging to study the 
demethylating effects of nucleoside analogs outside of in-vivo or cell culture systems. To 
circumvent this challenge we utilize a CD40L expressing murine fibroblast feeder cell 
line which, in conjunction with IL-4, induces limited proliferation in some human CLL 
primary cells in-vitro. Using this system we characterized the epigenetic changes to the 
CTA expression pattern in primary CLL cells. As shown in Figure 13C, we saw a marked 
increase in CTA transcription with 5A2 or LAQ alone, although maximal effects were 
only observed with the combination treatment. These data confirm our initial hypothesis 
by demonstrating robust CTA inducibility in primary cells using epigenetic modifiers. 
Epigenetic modifiers modulate the costimulatory profile and cytokine signaling of B-CLL.   
Prior studies indicate that treatment of specific solid tumors with HDACi can 
improve the costimulatory phenotype and can increase tumor immunogenicity(Khan, 
Magner et al. 2004; Tomasi, Magner et al. 2006; Khan, Magner et al. 2007; Khan, 
Gregorie et al. 2008; Khan and Tomasi 2008).  These data along with our prior studies 
using 5A2 on CLL led us to investigate the possibility that 5A2 and LAQ may potentiate 
an improved costimulatory phenotype in CLL.  Our flow cytometry profiling experiments 
revealed modest increases in the CLL cell line surface expression of CD86, CD80, HLA-
DR, CD40, and MHC class I (HLA-A,B,C) after treatment  with 1µM 5A2 and 25nM 
LAQ (Figure 14A).  In two additional repeat experiments this modest upregulation was 
consistent.  Given that CLL cells are inherently derived from APCs, it is possible that 
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even slight increases in the costimulatory phenotype may tilt the balance towards the 
formation of an anti-CLL immune response. 
Figure 14: Immunophenotype can be enhanced and secretion of IL-10, an 
immunosuppressive cytokine, abrogated by treating CLL cells with 5A2 and 
LAQ.  FACS analysis of three CLL cell lines (MEC1, MEC2, and WaC3) after 
treatment with 1uM 5A2 and 25nM LAQ reveals a moderate increase in costimulatory 
molecule surface expression when compared to untreated controls (grey histograms) 
(Panel A) mean fluorescent intensity (MFI) shifts are depicted for each histogram.  
Cytokine analysis by CBA showed significantly lower levels of IL-10 secretion in all 
CLL cell lines after 5A2+LAQ treatment (Panel B).  These data suggest that there 
may be changes to the functional immunogenicity of CLL cells after treatment with 
epigenetic modifiers. 
66 
Along with costimulatory molecules B-cells also provide critical 
immunostimulatory and immunosuppressive cytokine signals.  B-CLL cells in particular, 
secrete high levels of immunosuppressive factors which inhibit the generation of anti-
CLL T-cell responses.  One such potent immunosuppressive factor is IL-10(Sjoberg, 
Aguilar-Santelises et al. 1996).  In light of this we decided to investigate the IL-10 
secretion by CLL cell lines after treatment with 5A2 and LAQ.  Results from our 
cytokine analysis indicated that 5A2 and LAQ had the potential to independently inhibit 
IL-10 secretion in particular cell lines, however the combination of both inhibitors was 
essential to obtain significant inhibition in all cell lines, indicating that combination 
5A2+LAQ therapy may release CLL-induced T-cell suppression (Figure 14B).   
DNA demethylation and histone acetylation cooperate to increase the potency of the CLL 
cell – T-cell interaction.   
Our results thus far point to improved antigen expression, costimulatory 
phenotype, and cytokine signaling which have been postulated to directly correlate with 
the formation of a healthy immunological synapse, or SMAC.  To further investigate the 
changes in the resulting immune synapse we utilized superantigen (sAg) stimulation via 
staphylococcal enterotoxins A and B to induce a TCR mediated response in healthy 
allogenic donor CD8 or CD4 purified T-cells.  As APCs we utilized 5A2 and LAQ 
treated CLL cell lines or alternatively healthy allogenic B-cells as a control.  Our 
confocal imaging data suggested that the untreated CLL cells rarely formed robust 
interaction complexes with either CD8 or CD4 T-cells.  In sharp contrast, after treatment 
with 5A2, LAQ, or both, SMAC complexes were readily abundant, robust, symmetrical, 
and concave, indicative of more effective and prolonged APC signaling (Figure 15A and 
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Figure 15: Demethylation and histone acetylation improves the quality of the 
immune-synapse between T-cells and CLL cells.  Purified healthy donor CD8 T-
cells (Panel A) or CD4 T-cells (Panel B) were allowed to conjugate with sAg pulsed 
CLL cell lines which were treated with 1uM 5A2, 25nM LAQ, both or neither drug 
(or allogenic B-cells) (blue stained) and were stained for actin polymerization (red) 
using phalloidin rhodamine.  Representative confocal images are presented of T-
cell/APC interactions for each of the three CLL cell lines under each of the treatment 
conditions.  Quantification of the conjugation events was conducted by scoring 
polymerization as either 0 = dysfunctional, unorganized, and unpolarized synapse, 0.5 
= somewhat organized, somewhat polarized, or 1.0 = fully formed, concave, and 
polarized synapse; data is presented with standard error of 100 individual events 
(Panel C).  Data indicated both an increased quantity and increased quality of immune 
synapses occurring between the allogenic T-cells and the CLL cells after treatment 
with epigenetic modifiers imparting some functional significance to the observed 
expression differences. 
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15B).  To quantify these data we manually counted and scored 100 synaptic events for 
each experiment (Figure 15C) according to the methodology developed by Ramsay et. al. 
and demonstrated in Figure 16(Ramsay, Johnson et al. 2008).  Data showed a significant 
shift towards increasingly numerous and robust interaction zones after treatment, with 
optimal actin polarization observed with combination 5A2+LAQ treatment. 
To further confirm our microscopy data, we conducted flow cytometric sAg-
induced conjugation assays between healthy allogenic CD8 or CD4 T-cells and our CLL 
cell lines.  As depicted in an example flow plot (Figure 17A) the percentage of TCR 
specific conjugated cells was determined by subtracting the conjugates forming in an 
unstimulated sample from those forming in the sAg stimulated sample.  Data obtained in 
this manner indicated that robust TCR mediated conjugation occurred with greater 
frequency in both CD8 and CD4 conjugates after treatment with 5A2 or LAQ.  In all 
cases maximal conjugation was observable after combined therapy (Figure 17B).  
Figure 16: Microscopic identification and of immune synapse between CLL cell 
lines and allogenic T cells.  Purified healthy donor CD8 T-cells were allowed to 
conjugate with sAg pulsed CLL cell lines which were treated with 1uM 5A2, 25nM 
LAQ, both or neither drug (blue stained) and were stained for actin polymerization 
(red) using phalloidin rhodamine.  White arrows indicate actin polarized T cells.  
Scoring of synapse events involves counting only T cells which directly interact with 
adjacent blue-stained APCs and have not been sheared from their interacting partner 
by the process of plating.  Interactions are scored with either a “0” indicating little to 
no actin polymerization, “0.5” indicating slight polarization, and”1.0” indicating 
strong polarization.  Interactions are counted until 100 events are recorded. 
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Epigenetic alteration can restore T-cell signaling capacity and lytic granule mobilization 
in the context of CLL.  
To this point our data has shown that epigenetic modifiers such as 5A2 and LAQ 
could enhance CLL cell – T-cell SMAC formation.  However, we also sought to 
demonstrate that intracellular signaling, a key component of a functional APC – T-cell 
interaction, was improved.  It has been well demonstrated that mitochondrial localization 
at the synaptic interface is directly associated with CRAC mediated calcium entry, an 
essential downstream signal required for T-cell activation(Oakes 2007; Quintana, 
Schwindling et al. 2007).  To determine if mitochondria were localizing along the SMAC 
complex in our experiments we performed immunofluorescent confocal microscopy of 
CLL cell – allogenic T-cell conjugates after treatment with our epigenetic modifiers 
(Figure 18A and 18B).  Our observations led us to conclude that mitochondrial 
localization was deficient in untreated CLL cell conjugates, but was qualitatively restored 
by treatment with 5A2 plus LAQ in both CD4 and CD8 T-cell conjugations. 
Primed CD8 T-cells utilize TCR mediated signaling to mobilize and eventually 
release lytic granules containing perforin, granzyme-B, and interferon gamma.  By 
immunofluorescent staining of perforin we found that appropriate SMAC F-actin 
polarization, mitochondrial localization, and lytic granule mobilization was improved in 
the CD8 T-cell conjugates after CLL cells had been treated with both epigenetic 
modifiers (Figure 18A).  These data serve to confirm our prior results and indicate a 
definitive signaling enhancement. 
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Epigenetically altered CLL APC signaling results in T-cells with Th1 polarization, 
increased proliferative capacity, and lytic activity. 
The functional significance of an improved CLL APC is, in part, determined by 
the polarization of the responding T-cells.  To characterize this polarization we sorted 
conjugates formed between CD4+ T-cells and CLL cells and restimulated them with 
PHA following a 48 hour rest period.  The cytokine profile was then measured using 
cytokine bead array.  Our data suggest that, the balance between Th1 and Th2 signaling 
([Th1]:[Th2]) was improved (increasingly Th1) after treatment with both inhibitors 
Figure 17: Epigenetic modification of CLL cells improves TCR-induced 
conjugation with both CD4 and CD8 T-cells.  FACS based conjugation assays were 
conducted between healthy allogenic T-cells and sAg stimulated CLL cell lines (or 
healthy allogenic B-cells) after treatment with 5A2, LAQ, both or neither.  TCR-
specific conjugation was ascertained by subtracting the sAg induced conjugation level 
from the basal allogenic conjugation level (example depicted in Panel A) data was 
then normalized to the untreated condition.  Treatment revealed reproducible and 
significant increases in TCR-specific conjugation levels between CLL cells after 
treatment with both inhibitors (Panel B).  These data supplement prior analyses and 
confirm the amplification of TCR-specific synapses between CLL cells and both CD4 
and CD8 T-cells. 
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Figure 18: Epigenetic modifiers improve the functionality of the immune-synapse 
between T-cells and CLL cells as indicated by recruitment of mitochondrion and 
perforin to the immune synapse.  Purified CD8 T-cells (Panel A) or CD4 T-cells 
(Panel B) were allowed to conjugate for 30 minutes with sAg stimulated CLL cell 
lines which were treated with 1uM 5A2, 25nM LAQ, both or neither drug (or 
allogenic B-cells) (blue stained) and were stained for F-actin polymerization (red) 
using phalloidin rhodamine, mitochondrion (green), and perforin (cyan) (CD8 only).  
Representative confocal images are presented of T-cell/APC interactions for each of 
the three CLL cell lines under each of the treatment conditions.  Data indicated 
increased functionality of immune synapses occurring between the allogenic T-cells 
and the CLL cell lines after treatment with epigenetic modifiers. 
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Figure 19: CLL cells treated with 5A2 and LAQ recover the functional capacity 
to induce Th1 cytokine responses, proliferation, and TCR-specific cytotoxicity in 
responder lymphocytes.  Cytokine analysis of sorted 5A2 or LAQ treated CLL cell – 
T-cell conjugates indicated polarization towards a Th1 type cytokine profile as 
depicted by the [Th1]:[Th2] ratio and the relative change to IL-10, IL-6, and IL-4 
concentration versus IL-2, TNF, and IFNγ concentrations (Panel A).  In a MLR 
lymphocytes of both the CD4 and CD8 lineage were induced to proliferate only after 
CLL target cells had been treated with 5A2 and LAQ, while healthy allogenic B-cells 
were capable of inducing proliferation regardless of treatment (Panel B).  
Additionally, we found increased TCR-specific cytotoxicity by FACS based analysis 
of T-cell/dead-CLL conjugates after treating the CLL cells with epigenetic modifiers 
and stimulating with sAg (Effector:Target = 10:1), as control non-sAg based 
conjugation between T-cells and dead-CLL cells was subtracted from the percentage 
displayed (Panel C).  . Cytotoxicity assays using untreated, 1µM 5A2 treated, 25nM 
LAQ treated, or 5A2+LAQ treated primary CLL cells with healthy allogenic CD8 T-
cells show higher cytolytic function, approaching that of a healthy allogenic reaction 
(Panel D). 
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 (Figure 19A).  For the MEC1 cell line, treatment completely restored cytokine signaling, 
while for the WaC3 cell line treatment constricted Th2 signaling predominantly 
decreasing IL-10, IL-4, IL-6 and IFNγ.  These data serve to highlight clinically observed 
differences in cytokine signaling amongst CLL patients as well as a potential 
methodology to restore therapeutic T-cell polarization. 
Proliferative self-renewal of antigen specific T-cells is a requirement in the 
context of sustaining any potential anti-tumor effect.  To determine the effects of 5A2 
and LAQ have on the proliferation of T-cells stimulated with drug-treated MEC1 CLL 
cells we CFSE stained healthy donor allogenic CD8 and CD4 T-cells and subjected them 
to mixed lymphocyte reactions.  As shown in Figure 19B a normal allogenic response 
between healthy B-lymphocytes and healthy allogenic T-lymphocytes (both CD8 and 
CD4) induces approximately 30% proliferation.  On the other hand, only CLL cells 
which had been treated with a combination of 5A2 and LAQ were capable of stimulating 
appreciable proliferation (22.7% for CD8 and 21.1% for CD4). This proliferation data 
served as evidence that the combined 5A2+LAQ treatment could potentiate significant 
functional improvements when compared to either drug alone. 
As a final indicator of proper APC function of CLL cells we wanted to examine 
the TCR mediated lytic ability of CD8 cytotoxic T-cells. To investigate this we utilized 
sAg mediated killing and analyzed the results by flow cytometry, quantifying the 
percentage of T-cells specifically conjugating with dead CLL cells in a sAg specific (or 
TCR specific) manner(Vitale, Zamai et al. 1991; Morgan, Labno et al. 2001).  Results 
from this analysis showed improved lytic function of allogenic CD8 T-cells after being 
stimulated with 5A2+LAQ treated CLL cells (Figure 19C).  Significance (P<0.01) was 
74 
achieved in the WaC3 and MEC1 cell lines, correlating with and corroborating prior 
evidence of APC functionality. 
5-aza-2’-deoxycytidine and LAQ824 enhance allogenic CD8 cytotoxicity against early 
stage primary CLL cells. 
It is well established that CLL cells are deficient in their ability to stimulate T-cell 
responses, even in allogenic MLR (Figure 19B).  It has also been established that the 
level of dysfunction is directly correlated to increased RAI staging(Ramsay, Johnson et 
al. 2008).  To ensure that our in-vitro results hold true in primary CLL, we conducted 
cytotoxicity assays using allogenic CD8 T-cells and 5A2 or LAQ treated primary CLL 
cells.  We found that when primary purified CLL cells were treated with 5A2 and LAQ, 
there was a significant increase in allogenic cytotoxic potential above that seen in either 
drug treatment alone (Figure 19D).  These results indicate that combined 5A2+LAQ 
therapy may increase the APC potential of primary CLL. 
Discussion 
Our studies unveil a previously unknown effect of 5A2 and LAQ on the 
immunobiology of B-CLL.  As anticipated, our results show a therapeutic improvement 
in antigenic protein expression, costimulatory potential, cytokine signaling, SMAC 
synapse formation, and T-cell stimulation.  These changes reinforce the three signals of 
APC function: antigenic peptide (signal 1), costimulation (signal 2), and cytokine 
stimulation (signal 3), resulting in functional changes which may benefit current 
immunotherapeutic approaches for CLL.   
One caveat to our studies is that the majority of mechanistic experimentation has 
been carried out in CLL cell lines.  In our experience, the treatment of primary CLL cells 
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in-vitro with proliferation-dependent epigenetic modifiers such as 5A2 can be quite 
tedious, requiring the addition of external cytokines, growth factors, and feeder cells, 
making primary cells inappropriate for large scale reproducible molecular assays.  To 
avoid such pitfalls, our approach focused on validating the CLL cell lines as appropriate 
epigenetic surrogates of primary CLL cells and utilizing them for the short term in-vitro 
treatments necessary to foster an enhanced understanding of the mechanisms behind CLL 
cell epigenetic dysfunction.  Subsequently we confirm increased immunogenicity and 
epigenetic upregulation of potential target antigens using primary CLL cells to ensure the 
accuracy of our final conclusions.  In addition to our independent validation, other 
investigators have found these cell lines ideal for studying CLL epigenetics(Plass, Byrd 
et al. 2007; Chen, Raval et al. 2009). 
We postulate that the B-CLL cells are capable of directly presenting cancer 
antigens to the immune system, however it is likely that cross-presentation of CLL 
antigens via dendritic cells (DCs) is also occurring.  In our experience, treatment of DCs 
with epigenetic modifiers consistently inhibited the production of IL-10.  Such an effect 
was accompanied by an increased expression of co-stimulatory molecules and enhanced 
production of pro-inflammatory mediators.  In addition, HDACi-treated APCs were 
capable of effectively priming naïve antigen-specific CD4 T-cells and restoring the 
responsiveness of anergic CD4 T-cells isolated from tumor bearing mice (Wang et. al. 
unpublished observations).  These studies led us to unveil a novel role for HDAC11, in 
particular, as a transcriptional repressor of IL-10 in murine and human APCs, providing 
one potential molecular mechanism which we plan to specifically examine in the setting 
of CLL(Villagra, Cheng et al. 2009). 
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Our studies did not directly focus on the direct cytotoxic effect of HDAC and 
DNMT inhibitors; instead we focused our efforts on the epigenetic changes which result 
in improved immunological function.  In preliminary in-vitro testing we established a 
working concentration of 1µM for 5A2 and 25nM for LAQ which demonstrated 
negligible direct cytotoxicity over the 72 hour treatment, as measured by Annexin V  and 
propidium iodide staining, yet yielded sustained epigenetic effect, as measured by CTA 
upregulation or histone acetylation.  Although we cannot rule out the possibility that 
autophagy may occur(Fink and Cookson 2005), we have demonstrated quantifiable 
epigenetic changes which could conceivably be independently responsible for the 
demonstrated functional modifications.  In addition, although our studies do not directly 
focus on treating T-cell and instead focused on the polarization of T-cells by treated CLL 
APCs , preliminary data from our laboratory suggest that these drugs do not negatively 
affect the proliferation or IFNγ production capacity of primary CD4 and CD8 T-cells .  
Future ongoing studies in our laboratory will focus on the direct effects of epigenetic 
modifiers on the T-cells themselves (Dubovsky et. al. unpublished observations). 
It has been suggested that the survival of CLL hinges upon the balance between 
receiving lymphocyte activation, survival, and proliferation signals while maintaining 
immunosupression of the remaining healthy lymphocyte compartments(Tangye and 
Raison 1997; Rossmann, Lewin et al. 2002).  This model implies that a given CLL clone 
may preserve this balance in a different manner explaining the heterogeneity we see in 
the disease.  Our results elucidate some of these subtle differences and provide a potential 
mechanism for tilting the balance towards immune stimulation.  This balance is 
exemplified in our costimulatory phenotyping experiments (Figure 14A) which 
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demonstrated that slight to moderate improvements in the surface expression of 
costimulatory and MHC molecules can facilitate the changes seen in the SMAC complex.  
Our studies confirm the current understanding that slight alterations to APC molecular 
machinery enable CLL cells to facilitate their own survival while circumventing or 
diverting T-cell stimulation.  It is also possible that the epigenetic modifiers alter 
functional affinity and avidity of certain costimulatory molecules. 
Our studies focused on drug treatment and its effects on B-CLL immunology.  
However, in the clinical setting it is unlikely that these inhibitors will be so exclusive in 
their actions.  In prior studies we have demonstrated that the epigenetic effects of 5A2 do 
preferentially act on malignant cells, potentially due to deregulation of the chromatin 
packaging machinery such as DNA methyltransferase I (DNMT1) or brother of the 
regulator of imprinted sites (BORIS)(Klenova, Morse et al. 2002; Loukinov, Pugacheva 
et al. 2002; Vatolin, Abdullaev et al. 2005; Dubovsky and McNeel 2007).  Our previous 
efforts also indicate a potential for drug treatment to elicit long term molecular changes 
specifically in cancer cells, allowing for temporal separation of drug treatment and 
effector reaction.  Additional evidence comes in the form of studies conducted by Guo et. 
al. demonstrating elimination of lung metastases by CTA specific cytolytic T-
lymphocytes in a murine mammary carcinoma model after treatment with 5A2(Guo, 
Hong et al. 2006). 
Altogether, our results suggest that epigenetic modifiers which release chromatin 
constriction via DNA demethylation and histone acetylation may effectively restore the 
functional immunogenicity of chronic lymphocytic leukemia by inducing the expression 
of novel and highly antigenic tumor targets, increasing costimulatory potential, repairing 
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defective SMAC formation, and rectifying cytokine stimulation.  These effects could aid 
in the generation of more robust TCR mediated cytolytic responses in primary CLL. 
Materials and Methods 
Subject Populations 
Sera and peripheral blood mononuclear cells (PBMCs) were obtained from 
patients with CLL.  All subjects gave written institutional review board (IRB)-approved 
informed consent for their blood products to be used for research.  Blood was collected at 
the H. Lee Moffitt Cancer Center (Tampa, FL). PBMCs were stored in 1ml aliquots at -
140°C and sera were stored in aliquots at -80°C until used. 
Cell Culture and Drug Treatments 
Unless otherwise stated cells were cultured in-vitro at 37°C and 5%CO2 using 
RPMI1640 medium supplemented with 10% fetal calf serum and antibiotics.  The MEC1, 
MEC2, and WaC3 cell lines were kindly provided by Dr. John Byrd at Ohio State 
University and were previously characterized in the following references(Wendel-
Hansen, Sallstrom et al. 1994; Stacchini, Aragno et al. 1999).  Drug treatments were 
carried out on the CLL cells (separate from T-cells) for 72hr in complete medium using 
either 1uM 5-aza-2’-deoxycytidine (5A2), 25nM LAQ824 (LAQ), 1uM5A2 + 25nM 
LAQ, or neither.  At the conclusion of treatment cells were washed twice using pre-
warmed serum-free RPMI1640 and subjected to the various assays.  For treatments 
involving primary CLL cells, cultures of purified B-CLL cells (>95% purity) were 
maintained in 6 well plates atop irradiated (30Gy) monolayers of CD40L expressing 
murine fibroblasts (a kind gift from Dr. John Gordon at the University of Birmingham) in 
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the presence of 500U/ml recombinant human IL-4 (Research Diagnostic Inc., Concord, 
MA) 
Reverse Transcriptase-PCR (RT-PCR) 
Total RNA was prepared from pelleted cells (RNeasy mini columns and RNAse 
free DNAse, Qiagen, Valencia, CA) or was commercially obtained (BioChain, Hayward, 
CA).  RT-PCR reactions were conducted using the Qiagen one-step RT-PCR kit (Qiagen) 
with transcript-specific primers and total RNA from CLL cell lines as templates.  RT-
PCR amplification reactions were resolved on 2% agarose gels and the size of the 
amplified transcript confirmed by comparison with a standard DNA ladder (GelPilot 1Kb 
Plus Ladder, Qiagen).  Heatmap depictions were created using Image Quant 5.1 software 
(Molecular Dynamics) and the Heatmap Builder tool kindly provided by the Quertermous 
lab at Stanford.  
Cell Conjugation Assays 
Healthy or malignant B-cells were stained with CellTracker Blue (PKH26 for 
flow cytometric analysis) following the manufacturer’s instructions and pulsed with or 
without 2ug/ml of a cocktail of staphylococcal superantigens (SEA and SEB; Toxin 
Technologies; Sarasota, FL) for 30min at 37°C.  B-cells were then centrifuged (200g for 
5min) with 5 times the number of T cells stained with mitotracker deep-red (Invitrogen, 
Carlsbad, CA) (or CFSE for flow cytometric analysis ) and were incubated at 37°C for 
10min unless otherwise stated, then plated onto poly-L-lysine slides and fixed using 3.7% 
formaldehyde in PBS for 15min.  Additional antibody staining was conducted using 1:50 
anti-perforin (Pierce, Rockford, IL) followed by 1:125 anti-mouse FITC (Sigma).  
Microscopic acquisition and analysis of immune synapses was conducted using a Leica 
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upright fluorescent confocal microscope with the associated software according to the 
methods developed by Ramsay et. al.(Ramsay, Johnson et al. 2008).  Controls which 
lacked sufficient conjugation to acquire microscopic images (controls without SEA/SEB, 
without APCs, or without T-cells) were investigated and documented in low-resolution 
wide-field images showing no significant conjugation, unless otherwise stated.  All 
microscopy experiments were repeated three independent times unless otherwise stated. 
Flow Cytometry Immunophenotyping 
Flow cytometric analysis of cultured cells was performed using fluorochrome-
labeled monoclonal antibodies (mAbs; anti-HLA-A,B,C, -HLA-DR, -CD40, -CD80, -
CD86, -CD19, and –CD20, Becton Dickinson, San Jose, CA and eBiosciences, San 
Diego, CA)  and the viability dye 4',6-diamidino-2-phenylindole (DAPI, Sigma).  For 
CFDA-SE (CFSE) staining cells were resuspended in 0.5µM CFSE (Invitrogen) in RPMI 
medium for 15 minutes at 37°C followed by a wash and additional 30 minute incubation 
in serum supplemented medium prior to resuspension in culture medium.  For 
conjugation based T-cell phenotype experiments cells were allowed to conjugate 
according to the methods described in cell conjugation assays and conjugated cells were 
stained for anti-CD20 and anti-CD4.  Conjugation events were sorted using a FACS Aria 
cell sorter and separate populations were assayed for cytokine production using CBA 
array. Cytokine bead array (CBA) (Becton Dickinson) was conducted according to the 
manufacturers published protocol using cellular supernatant from three replicate 
experiments.  PKH26 staining was carried out and data was acquired on an LSRII 
cytometer (Beckman Coulter), and analyzed with FlowJo software (Tree Star, Ashland, 
OR).  For analysis    
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Mixed Lymphocyte Proliferation 
CLL cells or healthy B-cells were incubated in serum supplemented RPMI1640 
(Invitrogen) with allogenic, ficoll density gradient separated, PBMCs from a healthy 
donor which had been stained 30 minutes prior with 0.5µM CFSE at a 1:10 
effector:target (E:T) ratio.  Cultures were maintained at 37°C for 60 hours and were 
subsequently subjected to flow cytometric analysis.  Viability dye was used to gate out 
dead cells, CD4 and CD8 cells were stained using spectrally separate fluorophores and 
were individually investigated for CFSE dilution resulting from proliferation. 
FACS Based Cytotoxicity Assay 
Healthy allogenic T-cells were stained with CFSE as previously described.  CLL 
cells were pulsed with SEA and SEB superantigens at 2ug/ml for 2 hours and were 
centrifugally collected and incubated with T-cells at a 1:10 E:T ratio for 45 minutes at 
37°C in serum-free RPMI1640.  Cells were then carefully chilled to 4°C, centrifuged, and 
resuspended in FACS buffer containing the viability dye propidium iodide.  FACS 
analysis was immediately conducted and the percentage of T-cells conjugated with dead 
cells was tracked and compared to a T-cell only control.  Cytotoxicity analyses were 
conducted in triplicate and experiments were repeated at least twice. 
Lactate Dehydrogenase (LDH) Cytotoxicity Assay 
Allogenic CD8 T-cells (or B-cells) were separated from healthy donor ficoll 
density purified PBMCs using magnetic negative selection on an MACS LS magnetic 
column (Miltenyi Biotec, Auburn, CA) using the manufacturer specified protocol.   CD8 
T-cells and purified primary CLL B-cells (>95%) were washed twice with 37°C 
RPMI1640 without phenol red/1%FCS.  Cells were then incubated together at 1:100, 
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1:50, and 1:25 E:T ratios in RPMI1640 without phenol red/1%FCS in 96 well round 
bottom plates for 4 hours at 37°C/5%CO2.  Cytotoxicity was measured using the 
cytotox96 non-radioactive LDH assay kit according to the manufacturers published 
protocol (Promega, Madison, WI).  Control wells corresponding to minimum cytotoxicity 
(targets alone), maximum cytotoxicity (Triton X100 lysed targets), and culture medium 
alone were used to calculate experimental sample percent lysis. 
Statistical Analysis 
Unless otherwise stated, all continuous data conducted in replicates were analyzed 
using a two tailed Students T test.  P values are displayed on the graph to indicate the 
level of significance.  Error bars presented on graphical representations of data indicate 
standard deviation unless otherwise stated.  
Chromatin Immunoprecipitation (ChIP)  
After 72 hours treatment with 5-aza, LAQ, 5’-aza + LAQ or DMSO control (no 
treatment) cells were crosslinked with 1% formaldehyde and incubate with rotation at 
room temperature.  After 10 minutes, reactions were stopped by the addition of glycine to 
a final concentration of 0.125M.  Cells were washed twice with ice cold PBS and 
resuspended in ice cold TX-100/NP40 buffer (10mM Tris pH 8.1, 10mM EDTA, 0.5M 
EGTA, 0.25% TX-100, 0.5% NP40, 1mM PMSF, 0.5x Protease inhibitors) at a density of 
4x106 cells/ml.  Cells were re-suspended in 10ml ice cold Salt-wash buffer (10mM Tris 
pH 8.1, 1mM EDTA, 0.5M EGTA, 200mM NaCl,1mM PMSF, 0.5x Protease inhibitors) 
and incubated for 10 minutes at 4 oC.  Cells were lysed by adding sonication buffer 
(10mM Tris pH8.1, 1mM EDTA, 0.5M EGTA, 1% SDS, 1mM PMSF, 1x Protease 
inhibitors) at a cell density of 1x106 cells/30µl. Lysate was sonicated using a water bath 
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sonicator (Diagenode).  Chromatin immunoprecipitation was carried out for 16 hours at 4 
oC  using 4.5x106 cells and 5µg of specific antibody (anti acetyl histone-H4)(Upstate) or 
5 µg of rabbit IgG (Upstate).  Immunoprecipitated chromatin was captured by incubation 
with pre-blocked protein A/G beads (Santa Cruz) for 4hrs at 4oC then washed 
sequentially with low salt wash (20mM Tris pH8.1, 2mM EDTA, 150mM NaCl, 0.1% 
SDS, 1% tritonX 100), high salt wash (20mM Tris pH8.1, 2mM EDTA, 500mM NaCl, 
0.1% SDS, 1% tritonX 100) and LiCl wash (10mM Tris pH8.1, 250 mM LiCl, 1% NP-
40, 1% sodium deoxycholic acid, 1mM EDTA).  DNA was eluted with elution buffer 
(10mM Tris pH8, 1% SDS, 1mM EDTA) and crosslinks were reversed by incubating 
with 312 mM NaCl at 65oC for 4 hours. The immunoprecipitated DNA was treated with 
RNase (Ambion) for 30 minutes at 37oC and proteinase K (Roche) for 1 hour at 45oC. 
The DNA was purified with Qiagen PCR spin columns per manufacturer’s instructions.  
Purified DNA was analyzed by quantitative PCR using primers to the CNS+18 region of 
the human IFNγ locus (FWD 5’-GACTGGGTGAGGGAGATTG-3’, REV 5’-
GGGAGTGACAGGTAGGGAGA-3’) using an annealing temperature of 55°C.  Data 
was analyzed by calculating enrichment for acetylation versus IgG using percent input of 
each sample. 
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Chapter Four: 
Molecular, epigenetic, and phenotypic repolarization of T lymphocytes from chronic 
lymphocytic leukemia patients using 5-aza-2’-deoxycytidine. 
Abstract 
T cell immune dysfunction has an important role in the profound immunosupression that 
characterizes chronic lymphocytic leukemia (CLL).  Improper polarization of T cells has 
been proposed as one of the mechanism involved. Mounting data implicates chromatin 
regulation, namely promoter methylation, in the plasticity of naïve human T cells.  
Recent in-vitro evidence indicates that this plasticity may be phenotypically altered by 
using methylation inhibitors which are approved for clinical use in certain types of 
cancer. These results beg the question: can the ineffective polarization of T lymphocytes 
in the context of CLL be effectively modulated using methylation inhibitors in a 
sustainable therapeutic fashion?  To answer this question our laboratory has studied the 
effects of 5-aza-2’-deoxycytidine (5A2) in helper and cytotoxic T lymphocytes from 
healthy donors and CLL patients in well characterized molecular and epigenetic signaling 
pathways involved in effective polarization.  Moreover, we sought to investigate the 
consequences of methylation inhibitor treatment on lymphocyte survival, activation 
intensity, and naïve cell polarization. Our data indicates that 5A2 treatment can repolarize 
Th2 cells to effectively secrete interferon gamma, signal via T-bet, and achieve 
demethylation of critical Th1 specific promoters. Moreover, we demonstrate that 5A2 can 
force Th1 polarization of naïve T cells despite a strong IL-4 stimuli and a lack of IL-12.  
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In conclusion our data seeks to define a modality in which improper or ineffective T cell 
polarization can be altered by  5AZA and could be incorporated in future therapeutic 
interventions.  
Results 
T lymphocytes display phenotypic Th1 repolarization after treatment with 5A2 
To understand the activity of DNA methyltransferase inhibitors (DNMTi) on T 
helper cell polarization we examined the effects of a single dose of 5A2 (0.3µM, 1µM, 
3µM, 10µM, and 30µM) on fresh CD4 T lymphocytes obtained from healthy blood 
donors.  Intracellular staining revealed an increase in IFNγ (Th1 cytokine) positive cells, 
ranging from 10-13% at baseline to 39% in the 30µM dosage (Figure 20A).  To identify 
any potential detriment to CD8 T lymphocyte responses we examined IFNγ production in 
CD8 T cells from healthy donors and observed a similar increase which directly 
correlated with drug treatment (Figure 21).  
To more specifically address alterations to Th2 cells we conducted phosflow 
analysis of pSTAT6 levels in CD4 T cells from healthy donors.  Since pSTAT6 levels in 
Th2 cells quickly rise following activation via CD3ζ and CD28 we conducted a 
timecourse analysis spanning 15 to 75 minutes post activation(Chapoval, Dasgupta et al. 
2010).  Interestingly, pSTAT6 was found to decrease with drug treatment indicating that 
Th2 signaling patterns were abrogated by the DNMTi (Figure 20B). 
 To better understand the effects of 5A2 on Th1 and Th2 cell populations in-vitro 
polarized T cells were subjected to 5A2 treatment and the secreted levels of IFNγ were 
measured by CBA (Figure 23A and Figure 22).  The results confirmed that IFNγ 
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production in Th2 cells increased in a dose dependent manner with 5A2.  It was also 
noted that Th1 cells produced more IFNγ, however this was less pronounced. 
 In addition we tested the resulting polarity of 5A2 treated naïve cells after 
stimulation under strong Th1 or Th2 polarizing conditions using intracellular staining of 
Figure 20: Intracellular staining reveals 5A2 induced IFNγ and reduced 
pSTAT6.  Magnetically isolated CD4+ T cells from healthy donors were treated with 
5A2 (30, 10, 3, 1, 0.3, and 0µM) or left untreated and stimulated in-vitro prior to 
FACS analysis. A) Intracellular levels of IFNγ and IL-4 after 12 hours of 
PMA/ionomycin stimulation.  B) T cells were assayed for intracellular pSTAT6 at 
various timepoints after stimulation with αCD3 and αCD28 (15, 30, 45, 60, and 75 
minutes) all percentage data were normalized to an untreated and unstimulated 
sample.  All experiments were repeated at least three times with various healthy 
Figure 21: 5A2 increases IFNγ response in CD8 T cells from a healthy donor.  
Purified and PMA/ionomycin stimulated CD3+ T cells were treated with the indicated 
concentration of 5A2 and assayed via flow cytometry for CD8α and intracellular 
IFNγ.  Cells were gated on CD8+ and the gated population represents IFNγ positive. 
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IFNγ and IL4.  As expected, in the control sample Th2 polarizing conditions resulted in 
exclusively IL4 secreting cells, however 5A2 was capable of eliminating the IL4 
response and inducing the secretion of IFNγ in a dose dependent manner (Figure 23B).  
Our data also confirmed that Th1 polarizing conditions resulted in exclusive IFNγ 
production which was further exacerbated by 5A2 treatment. 
T cells from CLL patients alter polarization towards Th1 in response to 5A2 
 It has been previously demonstrated that T cells from CLL patients generally 
proliferate poorly after in-vitro stimulation with low IL2 (20U/ml) and secrete high levels 
of IL4, and relatively low levels of IFNγ(Scrivener, Kaminski et al. 2001; Frydecka, 
Kosmaczewska et al. 2004).  Given our previous data we wanted to test the repolarizing 
effects of 5A2 on these cells.  We started by examining the IFNγ secreted by T cells 
isolated from four CLL patients using CBA.  Our results matched the characteristic dose-
dependent increase in IFNγ revealed earlier in healthy donor T cells (Figure 24A).  These 
results were further confirmed using intraceullular staining to examine the levels of IFNγ 
Figure 22: In-vitro polarized Th1 and Th2 T cells have divergent expression of T-
bet and GATA3 by qRT-PCR.  mRNA analysis of 5 week in-vitro polarized Th1 
and Th2 cultures reveals that Th1 cells express relatively high levels of T-bet 
meanwhile Th2 cultures express relatively high levels of GATA3 indicating polarity. 
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produced in response to stimulation (Figure 24B).  In addition, we found that the 
percentage of IL4 positive T cells decreased under 5A2 treatment, indicating that a high 
percentage of Th2 polarized cells were no longer responding to in-vitro stimulation via 
IL4. 
 As mentioned earlier, the proliferation of T cells from CLL patients after in-vitro 
stimulation is characteristically poor, thus we were curious if 5A2 treatment could 
alleviate this anergic condition.  Using MTX proliferation assays we found that CD4 T 
cell proliferation directly correlated with 5A2 dose resulting in a 500% increase in 
proliferation compared to untreated samples (Figure 24C). 
Th2 cells treated with 5A2 induce constitutive pSTAT1 signaling and express T-bet 
 The phenotypic alterations we have identified thus far must derive from a specific 
set of molecular signaling networks. T-bet is considered the master regulator of Th1 
phenotype and it is controlled by activated STAT1 signaling.  We decided to investigate 
the protein expression levels of T-bet and pSTAT1 in healthy donor and CLL CD4 T 
lymphocytes by western blot.  As depicted in Figure 25A T-bet in healthy donor CD4 T 
cells is expressed at a basal level, however treatment with 5A2 increases this expression.  
This correlates with the increased phosphorylation of Tyr 701 on STAT1.  Similar results 
were observed in T cells obtained from a CLL patient; however both T-bet and pSTAT1 
were not identified at a basal level (Figure 25B). 
 Our prior experiments revealed phenotypic repolarization was restricted to the 
Th2 cells, thus we wanted to confirm that molecular alterations in purified populations of 
Th1 and Th2 were restricted to the Th2 population.  Using western blot analysis on 
polarized T cells we identified an increase in pSTAT1 Tyr 701 in Th2 cells when treated 
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with 5A2.  Notably, pSTAT1 levels were maintained at a higher basal level in Th1 cells 
Figure 23: Th2 cytokine polarization is inhibited by 5A2 treatment.  A) IFNγ 
released by In-vitro polarized and 5A2 treated Th1 and Th2 T cells subjected to 24 
hours of stimulation with αCD3 and αCD28 was assayed via CBA.  Error bars 
represent the standard deviation of four replicate samples.  B) Intracellular staining of 
IL4 and IFNγ in magnetically isolated 5A2 treated naïve CD4 T cells from a healthy 
blood donor subjected to stimulation with αCD3 and αCD28 along with strong Th1 or 
Th2 stimulation (indicated under title). 
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Figure 24: T cells from CLL patients are phenotypically repolarized by 5A2.  
CD4 T cells were magnetically isolated from CLL patients, immediately subjected to 
5A2 treatments, and assayed for alteration to phenotype.  A) T cells secretion of IFNγ 
was measured using CBA.  Data represents the mean and standard deviation of 
triplicate samples of four independent CLL patients.  B) T cells from a CLL patient 
were assayed via FACS analysis for intracellular levels of IFNγ (top panel) and IL4 
(bottom panel) in response to 5A2 treatment and PMA/ionomycin stimulation.  For 
comparison histograms representing an unstimulated (red) and stimulated yet 
untreated (blue) sample are provided along with the relative percentage of positive 
cells for each histogram. C) Proliferation of T cells from CLL patients in response to 
αCD28 and αCD3 along with 20U/ml IL2 was interrogated using an MTX assay.  
Data are normalized to the untreated sample and the graph represents triplicate well 
from four independent CLL patients with error bars representing standard deviation. 
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potentially rendering any alteration of pSTAT1 levels by 5A2 less evident (Figure 25C 
and D. 
5A2 treatment of T cells stimulates a well characterized IFNγ autocrine loop 
 Our data identified a link between T-bet, pSTAT1, and 5A2 treatment of CLL and 
Th2 T cells.  We wanted to know if the demethylating agent was eliciting the expression 
and secretion of IFNγ thus inducing a well defined STAT1α mediated autocrine feedback 
loop.  To explore this possibility we decided to abrogate this autocrine loop using anti-
IFNγ.  Our experiments revealed that soluble IFNγ was directly linked to the activation of 
STAT1α in response to 5A2, confirming our hypothesis (Figure 26A).  To confirm that 
the IFNγ and T-bet were upregulated at the transcriptional level we conducted qRT-PCR.  
Figure 25: 5A2 induces pSTAT1 and T-bet signaling in T cells.  Magnetically 
purified 5A2 treated CD4 T cells from a healthy blood donor A) or a CLL patient B) 
were assayed via western blot for total cellular levels of pSTAT1 ant T-bet protein.  
In-vitro polarized C) Th2 and D) Th 1 T cells were assayed via western blot for 
pSTAT1.  For comparison β-Actin and total STAT1 levels were also included.  
Western blots are representative of three independent experiments. 
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Our examination of mRNA levels indicated that both T-bet and IFNγ mRNA were 
increased after 5A2 treatment (Figure 26B). 
5A2 treatment of CLL T cells specifically induces demethylation of the IFNG promoter 
 In order to link the phenotypic changes with the molecular alterations we 
observed it was necessary to provide a mechanism for 5A2 induced IFNγ expression.  
The IFNG locus spans a 110kb region on human chromosome 12.  Using methylation 
specific PCR and bisulfite sequencing we identified a region comprised of 200bp 
proximal to exon I of IFNG which was demethylated by 5A2 (Figure 27A, B, and C).  
Our results reveal the methylation percentage of two independent CpG sites was 
decreased in T cell populations from CLL patients after treatment with 5A2.  Although, 
using Methyl-ChIP, we tested other regions of the IFNG locus, including the Conserved 
noncoding sequence (CNS)-56kb, -54kb, -34kb, Intron I, +18-20kb, +24kb, +46kb, and 
+55kb, we could only identify significant alterations in methylation within the promoter 
Figure 26: pSTAT1 signaling is induced by autocrine IFNγ.  A) Magnetically 
isolated CD4 T cells from healthy donors were treated with 5A2 and αIFNγ as 
indicated and subjected to western blot for pSTAT1 and total STAT 1.  B and C) 
Total RNA obtained from magnetically isolated CD4 T cells from healthy donors 
were subjected to T-bet and IFNG transcript specific qRT-PCR.  Error bars indicate 
two times the standard deviation of the mean of three replicate experiments. 
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region (data not shown).  Notably, the basal methylation level of untreated CLL cells 
resembled the highly methylated state seen in purified Th2 T cells. 
In mouse studies it has been shown that the CNS-6kb region was divergently 
methylated in Th1 and Th2 cells.  Additionally, it has been postulated that 5A2 treatment 
demethylates this region resulting in transcription of the IFNG gene in human T cells.  
Figure 27: 5A2 specifically demethylates the IFNG promoter. A) Synthetically 
methylated, unmethylated, and gemomic DNA were assayed using methylation 
specific PCR primers demonstrating transcript specificity.  B) MSP was carried out on 
bisulfite treated DNA obtained from Th1, Th2, and CD4 T cells obtained from CLL 
patients treated with various concentrations of 5A2 in addition to synthetically 
methylated and unmethylated DNA samples. C) Bisulfite sequencing of the promoter 
region of the IFNG locus confirms MSP results.  For methylation analysis the relative 
level of methylation for three independent experiments is depicted along with error 
representing the standard deviation.  Note that the graphical range is abbreviated for 
graph clarity.  D) A graphical depiction of our proposed signaling model in which 
5A2 induces ectopic demethylation, expression, and secretion of IFNγ resulting in 
autocrine IFNGR signaling via pSTAT1α a known T-bet transcription factor resulting 
in T-bet expression. 
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Our studies confirmed the notion that Th1 and Th2 cells differ in their respective 
methylation levels within the CNS-6kb region using bisulfite sequencing, however after 
detailed analysis using bisulfite sequencing we could not confirm demethylation in T 
cells after treatment with 5A2 indicating that this region is not responsible for the 
phenotypic and molecular changes in T cell polarity that we have identified (Figure 28A 
and B).    Figure 27D shows our proposed schema for the activation of T-bet using 5A2 
based on the evidence at hand. 
Discussion 
 The heritable epigenetic alterations which underpin T cell polarity can also 
become chromatin-based patterns which are altered in disease states.  Our studies have 
shed light on a potential mechanism by which therapeutic application of demethylating 
agents such as 5A2 can induce the signaling patterns of Th1 phenotype in what would 
generally be considered Th2 T cells.  We have also demonstrated this in a disease state, 
Figure 28: 5A2 does not induce demethylation of the CNS-6kb region of the 
IFNG locus.  A) Bisulfite sequencing analysis of the CNS-6kb region of the IFNG 
gene revealed divergent patterns of methylation between Naïve, Th1, Th2, and CLL T 
cells however B) no change was identified in CLL T cells after treatment with various 
concentrations of 5A2.  Note that the graphical range is abbreviated for graph clarity. 
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CLL, for which Th2 polarization regularly results in the inability to adequately deal with 
external pathogens.  As of yet it is uncertain how long these molecular alterations can 
persist in the absence of continued 5A2 treatment.  In unpublished studies we have 
identified phenotypic changes which continue for weeks post treatment and our ongoing 
studies will work to identify any temporal limitations to these chromatin modifications.  
It is conceivable, that even temporary alteration of T cell phenotype may have an impact 
in the T cell imunosuppression seen in patients with CLL. 
 With the general goal of chemotherapeutic effect many of the clinical trials to 
date have used concentrations of 5A2 which are detrimental to the healthy lymphoid 
compartment.  We too have occasionally witnessed a reversal of immunotherapeutic 
effects at higher doses of 5A2 (30µM or higher).  A recent clinical trial has been 
conducted using a relatively low dose 5A2 in CLL patients.  While 5A2 alone 
demonstrated little cytotoxic effect on CLL cells the 10mg/m2 dosage was well tolerated; 
unfortunately however, the effects to T lymphocytes were not studied(Blum, Liu et al. 
2010).  In a similar Phase I study of T-cell lymphomas 5A2 at 10mg/m2 reduced global 
DNA methylation in T lymphocytes by 2.5-6%, lending credence to the idea that sub-
chemotherapeutic levels of demethylating agents may alter the methylation of the T cell 
compartment(Stewart, Issa et al. 2009).   
 Currently, there is scant evidence regarding the regulation of IFNG in human T 
lymphocytes, however regulation in mice has been comprehensively studied by CB 
Wilson(Schoenborn, Dorschner et al. 2007).  A single manuscript has previously 
identified the epigenetic repolarization of human tumor infiltrating lymphocyte clones 
using 5A2, however the scope of this study lacked a detailed analysis of the mechanism 
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and molecular phenotype(Janson, Marits et al. 2008).  In prior published studies we 
identified a number of demethylation-induced immunotherapeutic effects which in total 
lead to an increased antigen presenting phenotype in CLL cells, a result which 
complements our current findings(Dubovsky, Wang et al. 2010). 
 We have identified molecular signatures which parallel the increased IFNγ 
response.  The molecular signals recapitulate an expected Th1 T cell including T-bet, 
pSTAT1, and decreased pSTAT6.  To our knowledge we are the first to identify these 
molecular signature alterations in response to demethylating agents.  In addition, we have 
identified a region of the IFNG locus which is actively demethylated by 5A2 and 
potentially induces expression in T cells.  In previous reports using human T cells 
methylation of the CNS-6kb region of the IFNG locus was shown to mirror T cell 
phenotype.  Our studies clearly demonstrate that demethylation of the CNS-6kb region is 
not necessary for IFNG expression and a Th1 phenotype.  It remains unclear why the 
CNS-6kb region was unchanged by 5A2 however it is possible that this region may be 
progressively demethylated as a Th1 clone expands, further reinforcing Th1 polarity. 
 Our findings generate provocative questions regarding the efficacy of new 
immunotherapeutic strategies based around 5A2.  Numerous studies have identified the 
induced expression of various cancer germline antigens in both solid and hematologic 
malignancy, including CLL(Dubovsky, Villagra et al. 2010).  A strategy which 
incorporated the restoration of T cell cytolytic capacity with the expression of potent 
immunotherapeutic antigens specifically within tumor cells would likely be attractive. 
Materials and Methods 
Subject Populations 
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Sera and peripheral blood mononuclear cells (PBMCs) were obtained from 
patients with CLL.  All subjects gave written institutional review board (IRB)-approved 
informed consent for their blood products to be used for research.  Blood was collected at 
the H. Lee Moffitt Cancer Center (Tampa, FL). PBMCs were stored in 1ml aliquots at -
140°C and sera were stored in aliquots at -80°C until used. 
Cell Culture, Drug Treatments, and T cell Polarization 
Unless otherwise stated cells were cultured in-vitro at 37°C and 5%CO2 using 
RPMI1640 medium supplemented with 10% fetal calf serum and antibiotics.  Drug 
treatments were carried out on plate-bound anti-CD3, soluble anti-CD28, and IL-2 
(20U/ml) stimulated magnetically isolated T cells (>95% purity) for 72hr in complete 
medium using the indicated concentration of 5-aza-2’-deoxycytidine (5A2) (dissolved at 
10mM in DMSO).  At the conclusion of treatment cells were washed twice using pre-
warmed serum-free RPMI1640 and subjected to the various assays (Supplementary 
Figure 1).  Th1 and Th2 polarized T cells were obtained from magnetically purified naïve 
human CD4 T cells by weekly stimulation with plate-bound anti-CD3, soluble anti-
CD28, and IL-2 (20U/ml) in the presence of IL-12 (10ng/ml) and anti-IL-4 (1:100) for 
Th1 or IL-4 (5ng/ml) and anti-IL-12 (1:100).  Medium was replaced twice weekly and 
stimulation was repeated for four weeks upon which a sample was collected and tested 
via CBA array and qRT-PCR for polarity (Figure 29). 
Reverse Transcriptase-PCR (RT-PCR) 
Total RNA was prepared from pelleted cells (RNeasy mini columns and RNAse 
free DNAse, Qiagen, Valencia, CA).  RT-PCR and qRT-PCR reactions were conducted 
using the Qiagen one-step RT-PCR kit (Qiagen) or the iScript SYBR green RT-PCR kit 
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 (BioRad, Hercules, CA) with transcript-specific primers (T-bet: 
5’TGACCCAGATGATTGTGCTC, 3’ATCTCCCCCAAGGAATTGAC) (GATA3: 
5’AAGGCAGGGAGTGTGTGAAC, 3’TGGATGCCTTCCTTCTTCAT) (IFNG: 
TTCAGATGTAGCGGATAATGGA, 3’TCAGCCATCACTTGGATGAG) and 200ng of 
total RNA.  RT-PCR amplification reactions were resolved on 2% agarose gels and the 
size of the amplified transcript confirmed by comparison with a standard DNA ladder 
(GelPilot 1Kb Plus Ladder, Qiagen).  qRT-PCR experiments were analyzed using the 
MyiQ software package.  After confirming a single melt curve peak CT values for Actin 
were compared to CT values for the transcript of interest using the 2-∆∆CT method. 
Flow Cytometry and Cytokine Bead Array 
Flow cytometric analysis was performed using fluorochrome-labeled monoclonal 
antibodies (mAbs; anti-CD3, -CD4, -CD8, -IL-4, -IFNγ, and anti-pSTAT6, Becton 
Dickinson, San Jose, CA and eBiosciences, San Diego, CA)  and the viability dye 4',6-
diamidino-2-phenylindole (DAPI, Sigma).  Intracellular staining of IL-4, IFNγ, and 
pSTAT6 was conducted according the appropriate manufacturer protocol (Becton 
Dickinson).  Cytokine bead array (CBA) (Becton Dickinson) was conducted according to 
the manufacturers published protocol using cellular supernatant from three replicate 
Figure 29: Schema for in-vitro experimental analysis of T cells.  Purified CD4 or 
CD8 T cells are stimulated using plate bound αCD3, soluble αCD28 and 20U/ml IL2 
for 72 hours in the presence of the indicated concentration of 5A2.  Cells are then 
washed and restimulated using the same methodology prior to analysis. 
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experiments.  Flow cytometric data was analyzed with FlowJo software (Tree Star, 
Ashland, OR) on a minimum of 30,000 collected events. 
Methylation Analysis 
 For both methylation specific PCR (MSP) and bisulfite sequencing purified DNA 
(Qiagen DNA miniprep kit, Qiagen) was bisulfite treated according to the manufacturer 
protocol using the Epitect Bisulfite treatment kit (Qiagen).  MSP was conducted using 
transcript specific primers designed to specifically recognize either methylated or 
unmethylated CpG motifs (IFNG-methyl 5’AAGAGTTAATATTTTATTAGGGCGA, 
3’TAAACTCCTTAAATCCTTTAACGAT) (IFNG-unmethyl 
5’TGAAGAGTTAATATTTTATTAGGGTGA, 
3’TAAACTCCTTAAATCCTTTAACAAT).  Touchdown PCR was utilized to generate 
PCR products which were subjected to gel electrophoresis, stained with ethidium 
bromide and densitometrically analyzed. 
Bisulfite sequencing was conducted using primers indifferent to methylation 
status (IFNG-Promoter 5’TAGAATGGTATAGGTGGGTATAATGG, 3’ 
ATAACAACCAAAAAAACCCAAAAC) (CNS-6kb 
5’TGAGTAAAGGTTTAGGGTATTTTTT, 3’ACTCACTACAAACTCTACCTCCC).  
PCR amplicons were cloned into plasmid vectors using a T-A cloning kit (Qiagen) and 
transformed bacterial colonies were directly sequenced using vector primers.  A 
minimum of 12 bacterial colonies were sequenced for each sample.  Sequencing results 
were used to calculate methylation status of CpG motifs and average methylation stats 
was depicted in graphical form. 
Western Blot Analysis 
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  Western blotting experiments were conducted using conventional methodology 
previously described(Dubovsky, McNeel et al. 2009).  Blotting was conducted using 
pSTAT1 Y701 (Cell Signaling Technologies, Danvers, MA), T-bet (eBiosciences), 
STAT1, and β-Actin (Santa Cruz Biotechnology, Santa Cruz, CA) specific antibodies. 
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Chapter Five: 
Scientific significance and future directions 
Antigen specific immunotherapy for CLL 
Vaccines in general have had wide-ranging success and, in fact, are the only 
means by which the human race has achieved eradication of a disease.  Unfortunately, 
however, vaccines are generally only effective when administered prior to challenge. 
  Active immunotherapeutic strategies are hardly a novel concept in solid tumors.  
For the past two decades immunotherapeutic vaccines have been tested, primarily in 
melanoma and renal cell carcinoma, which tend to be slightly more immunogenic in 
nature.  While many of these vaccine strategies and antigens have been ineffective in fast 
growing solid tumors there are a few select strategies which persist, among these are 
cancer testis antigen based cellular vaccines.   
In hematologic malignancies, namely CLL, antigen specific vaccines have not 
been studied in such a fervent manner.  Instead, much attention was initially devoted to 
the development of idiotype-specific vaccines which would elicit an immune response 
against the clonal CLL antigen receptor.  While this was a meritous concept, few trials 
have demonstrated success and, like antigen-specific vaccines for solid tumors, only a 
few permutations of this idea persist.  Nowadays, immunotherapeutics for CLL have 
followed the general trend initiated by the success of anti-CD20 monoclonal antibody 
therapy; however there exists little curative potential with conventional antibody therapy.  
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With the new era of epigenetics the novel concept of vaccinate-induce has the potential to 
recapitulate the twentieth century success of anti-viral vaccines. 
Our studies represent the first comprehensive identification of inducible antigens 
in CLL.  While true identification of circulating T cells capable of responding to CLL 
antigens is extremely difficult in CLL we were able to identify isotype-switched antibody 
responses. The generation of an IgG response towards any antigen requires isotype 
switching, a phenomenon which occurs in response to helper T-cell antigen recognition.  
Thus a robust IgG response to a given cancer-specific antigen can be an extremely 
informative event indicating the presence of a functional T-cell repertoire specific to the 
antigen; data which becomes vastly more important when you consider that CLL-induced 
antigen-specific T-cell inhibition tends to eliminate the majority of these clones.  One 
could envision that the most potent antigens should have no detectable immune 
responses.  Although this may also be true, it is now understood that cancer progression 
is marked by repeated immune-evasive events, leading to the epigenetic suppression of 
many highly antigenic proteins.  Immune-evasion conceivably leads to the generation of 
an antibody milieu specific to potent tumor antigens.  Thus finding a single response 
towards an antigen which is not expressed by the current tumor potentially indicates 1) 
epigenetic suppression of the antigen and 2) antigen expression leads to an immune 
response capable of eliminating a particular CLL clonal population. 
 In future studies it will be necessary to assess the efficacy of various inducible-
antigen based immunotherapeutic strategies.  Amongst the most promising is a novel 
strategy which utilizes patient T cells transfected with chimeric antigen receptors capable 
of responding to surface antigens on CLL cells.  Since the chimeric receptor is composed 
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of an antibody-based antigen recognition regions and T cell derived signaling the 
possibilities are not limited to MHC presented peptide antigens.  One conceivable 
permutation of this therapeutic tool would be to derive chimeric antigen receptors which 
recognize an epigenetically inducible surface antigen on CLL.  Conceivably, this antigen 
could even be an epigenetically induced carbohydrate molecule; a concept which is still 
in its virgin stage. 
Alleviating B cell dysfunction in CLL 
 In healthy individuals B cells play a critical role in promoting the adaptive 
immune response via presentation of antigens to the T lymphocyte wing of the immune 
system.  This antigen presentation normally provides costimulatory and cytokine signals 
which direct T cell polarization, proliferation, and effector function as well as inducing 
proliferation, isotype switching, and plasma cell differentiation of the B cell.  Since CLL 
patients progressively loose their healthy B cell compartment due to competition with the 
malignant clone these necessary functions of B cell immunity are lost.  In addition, the 
loss of normal B lymphocytes truncates the available naïve B cell pool, limiting the 
ability to respond to new pathogens. 
Clinically, this dysfunction poses a huge obstacle to effectively treating the 
disease.  Currently, the majority of approved therapeutic interventions, including anti-
CD20 monoclonal antibody therapy and chemotherapeutic agents such as fludarabine, 
have the capacity to kill both healthy and malignant B cells exacerbating the 
immunosupression.  In light of this, there is an obvious need for novel therapeutics which 
are significantly more specific in their cytotoxic efforts.  While many of the epigenetic 
modifiers, including 5-aza-2’-deoxycytidine and LAQ, were initially developed as 
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cytotoxic chemotherapeutic agents, their effect at sub-chemotherapeutic levels may lead 
to a more profound clinical advantage. 
Our studies demonstrated that using low doses of both hypomethylating and 
histone deacetylation agents resulted in an alteration of immune phenotype amongst CLL 
cells.  Importantly, we were able to effectively alter the antigen presentation signals such 
that Th1 T cell responses were enhanced, immune synapse signaling was improved, 
immunosuppressive cytokines were reduced, and CLL specific cytotoxicity was 
achievable.  Since our studies were focused on the malignant arm of the B cell repertoire 
it remains to be seen whether or not healthy B cells derived from the bone marrow will 
recapitulate healthy antibody responses alleviating the other half of B cell base 
immunosupression.  These studies will be most effectively carried out in animal model 
systems, a task which our lab actively seeks to carry out.   
In B-CLL the stromal environment has drastic impact on the survival, 
proliferation, signaling, and localization of tumor cells further complicating the transition 
from benchtop to bedside.  There currently exists a single mouse model which adequately 
recapitulates CLL.  Developed by Dr. Carlo Croce this mouse has the TCL1 oncogene 
under the transcriptional control of the antibody immunoglobulin µ promoter.  Recent 
molecular evidence suggests that the µTCL1 mouse model accurately mimics the stromal 
environment of CLL, inducing T-cell dysfunction and ignorance identical to that found in 
human CLL patients.  However, the unfortunate consequence of conventional murine 
models for immunotherapeutic research is that the antigens derived have variable 
conserved levels of peptide sequence, epigenetic control, cell specificity, and expression.  
In the past this has led to conclusions which were not translatable to the human system.   
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An alternative approach would be to utilize the new genetic stock of IL-2R 
common γ chain deficient NOG (NOD-SCID/IL-2Rγnull) mice for the implantation of 
human tissue.  These mice have demonstrated superior engraftment of human cells 
attributable to their lack of functional NK, B-, and T-lymphocytes.  In our preliminary 
work we have successfully engrafted B-CLL along with T-cells from patients within our 
PBMC bank enabling us to conduct preclinical studies, including immunotherapeutic 
strategies.  Another benefit is the ability to utilize human antigens as opposed to murine 
homologues of varying antigenicity as would be necessary in other spontaneous tumor 
models.  Although this research is still in its infant stages, this new model provides a 
necessary tool for preclinical testing of immunotherapeutic strategies which incorporate 
the alteration of B cell immunogenicity.  
Alleviating T cell dysfunction in CLL 
 While more indirect, the immunosuppressive effect CLL has on the T cell 
armament is no less profound.  In healthy individuals professional antigen presenting 
cells such as B cells are critically necessary for the appropriate licensing of CD4 helper 
and CD8 cytotoxic responses.  Although the complex interactions which take place 
between T cells and B cells in-vivo are still being studied, there are a few variables which 
have proven critical for effective T cell polarization.  First and foremost is adequate 
synapse formation.  Research indicates that synapse formation consisting of long lasting 
TCR engagement followed by costimulatory signals derived from interactions involving 
CD28 and stabilized by engagement of the ICAM1/LFA scaffolding promote memory 
cell formation, polarization, and proliferation of the recently mature lymphocyte clone. 
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 Interestingly, our research focusing on relieving B cell immunosuppressive had 
the unintended consequences of improving the dynamics of naïve T cell activation and 
polarization via interaction with CLL APCs.  Our data demonstrated that T cells 
interacting with epigenetically modified CLL cells were of Th1 polarity.  Evidence 
indicates that this leads to a cytotoxic response capable of eliminating intracellular 
pathogens such as virus infection or potentially even CLL cells. 
While the proper polarization of naïve T cells responding to new pathogens is 
important, it does not repair the damage which has already accumulated within the T cell 
repertoire of a CLL patient.  It is postulated that the T cell repertoire still contains the 
receptor diversity necessary to respond to numerous external pathogens and perhaps even 
CLL.  However, as a result of the CLL improper Th2 polarization, anergy, and the 
inability to form new antibody responses renders T cells powerless against the majority 
of challenges.  Our studies successfully demonstrated a methodology which could be 
utilized to regain Th1 functionality amongst T helper cells in CLL.  Moreover, we 
demonstrated that newly formed T cell responses could be therapeutically modulated as 
well.  All in all we have identified what may become a useful therapeutic tool for CLL. 
What remains unclear is whether or not a revitalized T cell compartment will, 
without further intervention, be capable of eliminating CLL cells.  We have started to 
investigate this hypothesis; however using conventional methodology it is difficult to 
isolate adequate CD4 and CD8 T cells along with CLL cells from a single blood donor.  
Moreover, in-vitro culture of T cells from CLL patients requires supra-physiologic 
concentrations of IL2.  For these reasons it would be ideal to directly test this hypothesis 
in an in-vivo tumor model.  A model such as the NOG/SCID model described earlier 
107 
would be ideal.  In preliminary studies we have identified a methodology which allows 
for selective engraftment of the CD3 T cell compartment allowing for experimental 
control animals to be generated alongside fully engrafted littermates. 
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